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ABSTRACT 
 
Spinal cord injury (SCI) results in a number of devastating consequences, including loss 
of motor function, paralysis, and neuropathic pain.  Concomitant peripheral tissue injury 
below the lesion site can result in uncontrollable nociception that sensitizes spinal 
neurons and promotes chronic pain.  Additionally, drugs like morphine, though critical 
for pain management, elicit pro-inflammatory effects that exacerbate chronic pain 
symptoms.  Currently, there is a lack of effective therapeutic mechanisms to promote 
regeneration at the lesion site, and a limited understanding of regulatory mechanisms 
that can be utilized to therapeutically manipulate spinal cord plasticity.  MicroRNAs 
(miRNAs) constitute novel targets for therapeutic intervention to both promote repair 
and regeneration, and mitigate maladaptive plasticity that leads to neuropathic pain.   
 Microarray and qRT-PCR comparisons of contused and sham rat spinal cords at 4 
and 14 days following SCI indicated that a total of 35 miRNAs were dysregulated, with 
miR1, miR124, and miR129 exhibiting significant down-regulation after SCI, and both 
miR21 and miR146a being transiently induced.  Localized expression of miRNAs and 
cellular markers indicated that changes in miRNA regulation favor the emergence of 
neural stem cell niches and reversion of surviving neurons to a pre-neuronal phenotype.  
Additionally, both uncontrollable nociception and morphine administration resulted in 
further dysregulation of SCI-sensitive miRNAs, along with their mRNA targets.  
Morphine administration significantly induced expression of both miR21 and IL6R 
expression, indicating that morphine-induced miRNA dysregulation is involved in the 
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promotion of neuroinflammation that drives increased pain-sensitivity.  Similarly, 
uncontrollable nociception significantly modulates expression of miR124, miR129, and 
miR146a, which inhibit cell cycle proteins and microglial activation, and dysregulation 
of these miRNAs, along with BDNF and IGF-1, likely contributes towards promotion of 
hypersensitivity in spinal neurons that underlies neuropathic pain.  Consequently, SCI-
sensitive miRNAs may constitute therapeutic targets for modulation of 
neuroinflammation and microglial activation in order to mitigate secondary injury, 
promote regeneration, and prevent maladaptive plasticity that drives neuropathic pain 
and exacerbation of chronic pain symptoms by morphine administration. 
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1. INTRODUCTION 
 
1.1 Epidemiology and Pathophysiology of Central Nervous System Injury 
The central nervous system (CNS) is highly vulnerable to injury, which can result in 
substantial cognitive and behavioral impairment.  Acute insult to the brain, such as 
traumatic brain injury (TBI) and ischemic stroke, is one of the most common causes of 
disability and death in adults (Sosin et al., 1996; Ghajar, 2000; Langlois et al., 2006; 
Donnan et al., 2008; Feigin et al., 2010).  In contrast, although it is a fairly uncommon 
cause of disability at an estimated 40 cases per million, spinal cord injury (SCI) 
commands a high socioeconomic cost out of proportion to its frequency (DeVivo, 1997; 
Jackson et al., 2004; Boswell et al., 2013).  Stroke is responsible for 10-12% of all 
deaths in western countries and projected to be the fourth most common cause of 
disability-adjusted life-years (DALYs; the sum of life-years lost as a result of premature 
death and years lived with disability adjusted for severity) by 2030, but the vast majority 
of deaths occur in the elderly population with only 12% of stroke related deaths 
occurring in people less than 65 years of age (Bonita, 1992; Lopez et al., 2006; Donnan 
et al., 2008; Feigin et al., 2010).  To the contrary, both TBI and SCI occur mostly in 
younger people, with the peak incidence of TBI between 15 and 24 years of age and the 
average age at injury for SCI patients ranging between 30 and 40 (Ghajar, 2000; Jackson 
et al., 2004; Feigin et al., 2010; Boswell et al., 2013).  Whereas stroke prevalence is 
mostly tied to risk factors such as hypertension, diabetes, and smoking (Donnan et al., 
2008; Feigin et al., 2010), the leading causes for TBI and SCI are motor vehicle 
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accidents, falls, and acts of violence (Ghajar, 2000; Jackson et al., 2004; Feigin et al., 
2010; Cripps et al., 2011; Boswell et al., 2013).  Moreover, injury results in the largest 
number of disability-adjusted life years lost, and as TBI and SCI tend to occur at a young 
age, the financial burden can be overwhelming (Murray and Lopez, 1997; Ghajar, 2000; 
Boswell et al., 2013).  In particular, SCI can be financially crippling, as high 
quadriplegia sustained at age 50 can have lifetime expenses up to $2.4 million, whereas 
the same injury sustained at age 25 can cost an estimated $4.3 million (Boswell et al., 
2013).  As SCI shares many pathophysiological characteristics with stroke and TBI, 
cross-analyses of the mechanisms of injury progression and their impact on functional 
recovery can grant insight into possibilities for new therapeutic strategies to improve the 
quality of life following spinal cord trauma and significantly reduce its socioeconomic 
impact.   
 As an immune privileged organ, the central nervous system regulates influx of 
immune cells and mediators, such as T and B lymphocytes, from the vasculature through 
strict maintenance and modulation of the blood-brain barrier and blood-spinal cord 
barrier, but acute CNS injury disrupts proper blood-brain and blood-spinal cord barrier 
regulation triggering an inflammatory response (Perry, 1998; Jordan et al., 2008; Kaur 
and Ling, 2008; Pan and Kastin, 2008; Sandoval and Witt, 2008; Ankeny and Popovich, 
2009; Schoknecht and Shalev, 2012).  While inflammation is typically beneficial for an 
organism in response to injury or the presence of pathogens, prolonged inflammation in 
the CNS following injury can have detrimental effects that drive secondary injury, 
leading to additional neurodegeneration and substantially worse functional outcomes 
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(Jordan et al., 2008; Benowitz and Popovich, 2011; Smith, 2013).  Brain and spinal cord 
inflammation consists of multiple components, including activation of microglia and 
astrocytes (Gomes-Leal et al., 2004; Lai and Todd, 2006; Jordan et al., 2008; Karimi-
Abdolrezaee and Billakanti, 2012; Smith, 2013), formation of cytotoxic reactive oxygen 
species (ROS; Bains and Hall, 2012; Kahles and Brandes, 2012), and up-regulation of 
key inflammatory mediators such as cytokines and chemokines (Ghirnikar et al., 1998; 
Segal, 2005; Lai and Todd, 2006; Pan and Kastin, 2008; Das et al., 2012; Lambertsen et 
al., 2012; Smith et al., 2012), which allows infiltration of immune cells by increasing 
neurovascular permeability (Jordan et al., 2008; Kaur and Ling, 2008; Pan and Kastin, 
2008; Sandoval and Witt, 2008; Ankeny and Popovich, 2009; Khatri et al., 2012; 
Oudega, 2012; Schoknecht and Shalev, 2012).  In addition, expression of neurotrophins 
and other growth factors, such as IGF-1, play a key role in injury mitigation through 
restoration of vascular integrity and promotion of neural survival (Lindvall et al., 1994; 
Hicks et al., 1999; Dluzniewska et al., 2005; Sharma, 2005a; Wu, 2005; Allen and 
Dawbarn, 2006; Sharma, 2007a; Madathil et al., 2010).  
 While medical complications after ischemic stroke are the major cause of 
mortality (Slot et al., 2009; Kumar et al., 2010; Schoknecht and Shalev, 2012), preceding 
brain edema and hemorrhagic transformation due to blood-brain barrier dysfunction can 
affect outcomes with potentially serious short and long-term consequences (Balami et 
al., 2011).  As such, early detection and mitigation of these neurological complications 
could substantially reduce stroke mortality and morbidity.  Stroke is unique with regards 
to other acute CNS injuries in that blood-brain barrier dysfunction during the initial 
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phase of injury is solely driven by an energy failure due to a lack of glucose and oxygen 
through vascular occlusion, as opposed to the direct endothelial damage in the 
vasculature that often occurs immediately after traumatic injury (Khatri et al., 2012; 
Schoknecht and Shalev, 2012).  Comparatively, blood-brain barrier dysfunction in TBI 
can also be delayed by several days, with subsequent edema formation accompanied by 
rises in intracranial pressure that mechanically impair blood flow, resulting in the 
development of an ischemic zone and secondary lesion progression (Rodriguez-Baeza et 
al., 2003; Shlosberg et al., 2010; Chodobski et al., 2011; Schoknecht and Shalev, 2012).  
Energy failure due to ischemic stroke triggers a cascade of processes that drive blood-
brain barrier disruption, including depletion of adenosine triphosphate (ATP), a rise in 
intracellular potassium, lactic acidosis, and release of extracellular glutamate (Kulik et 
al., 2008; Khatri et al., 2012).  The resulting ischemic environment results in increased 
blood-brain barrier permeability, reperfusion, and activation of astrocytes and microglia, 
which induces expression of pro-inflammatory cytokines (Khatri et al., 2012; 
Schoknecht and Shalev, 2012).  Although the underlying molecular changes that lead to 
blood-brain barrier breakdown after TBI are not completely understood, the mechanisms 
involved mirror those following cerebral ischemia, including microglia and astrocyte 
activation, and production of both free radicals and inflammatory mediators (Shlosberg 
et al., 2010; Schoknecht and Shalev, 2012).  In particular, interleukin-1-beta (IL-1β), 
interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) are three of the most 
commonly studied cytokines up-regulated following both ischemic stroke and TBI, and 
they play an important role in the progression of neuroinflammation (Ghirnikar et al., 
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1998; Jordan et al., 2008; Das et al., 2012; Lambertsen et al., 2012).  In stroke, activated 
microglia and macrophages predominately produce TNF-α and IL-1β (Buttini et al., 
1994; Davies et al., 1999; Lambertsen et al., 2005; Clausen et al., 2008; Lambertsen et 
al., 2012), while increased IL-6 expression is additionally observed in neurons (Suzuki et 
al., 1999; Suzuki et al., 2009; Lambertsen et al., 2012).  Contrarily, IL-1β, IL-6, and 
TNF-α are all induced in activated astrocytes in addition to microglia and macrophages 
following TBI (Sawada et al., 1995; Ghirnikar et al., 1998; Das et al., 2012).   
IL-1β is an important initiator of immune response, and its up-regulation 
promotes astrocyte proliferation and activation (Balasingam et al., 1994; Ghirnikar et al., 
1998; John et al., 2004; Jordan et al., 2008).   Increased IL-1β expression is associated 
with worse functional outcomes following both stroke and TBI, and its inhibition using a 
competitive receptor antagonist, neutralizing antibody, or mild immunosuppressant 
(minocycline) has been shown to significantly reduce infarct size and attenuate lesion 
volume, respectively (Yamasaki et al., 1995; Loddick and Rothwell, 1996; Boutin et al., 
2001; Sanchez Mejia et al., 2001; Touzani et al., 2002; Bye et al., 2007; Ziebell and 
Morganti-Kossmann, 2010; Lambertsen et al., 2012).  Likewise, TNF-α is a principle 
mediator of neuroinflammation, and its inhibition reduces both ischemic brain injury and 
improves neurological outcome in TBI through reduced blood-brain barrier dysfunction 
and brain edema (Shohami et al., 1997; Yang et al., 1998; Jordan et al., 2008; Ziebell 
and Morganti-Kossmann, 2010), while administration of recombinant TNF-α reverses 
the beneficial effects and worsens ischemic and traumatic brain damage (Barone et al., 
1997; Shohami et al., 1997).  However, TNF-α could also be neuroprotective, as TNF-α-
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receptor deficient mice present larger ischemic infarcts than wild-type mice (Bruce et al., 
1996; Jordan et al., 2008), pretreatment in ischemic, cerebral injury models through 
intracisternal administration of TNF-α significantly reduces infarct size and decreases 
microglial activation (Nawashiro et al., 1997), and mice deficient of TNF-α or its 
receptors have been shown to display exacerbated tissue and blood-brain barrier damage, 
as well as impaired neurological recovery after TBI (Scherbel et al., 1999; Sullivan et 
al., 1999; Ziebell and Morganti-Kossmann, 2010).   Contrarily, while both IL-1β and 
TNF-α are primarily implicated in negative effects following brain injury, IL-6 can 
potentially exhibit beneficial or detrimental effects depending on the pathologic context, 
and it has both direct and indirect neurotrophic effects on neurons (Benveniste, 1998; 
Suzuki et al., 2009; Ziebell and Morganti-Kossmann, 2010).  In the acute phase of 
ischemic injury, IL-6 promotes microglia and leukocyte activation and modulates acute 
inflammation by down-regulating the pro-inflammatory cytokines and up-regulating the 
anti-inflammatory molecules (Kharazmi et al., 1989; Chiang et al., 1994; Xing et al., 
1998; Suzuki et al., 2009).  Although increased plasma concentrations of IL-6 are 
associated with greater infarct volumes and worse functional outcomes in cerebral 
ischemia and with severe blood-brain barrier dysfunction in TBI (Kossmann et al., 1995; 
Castillo and Rodriguez, 2004; Smith et al., 2004; Jordan et al., 2008), enhanced 
production of IL-6 has been shown to be neuroprotective following cryolesion in a 
GFAP-IL-6 transgenic mouse model, and IL-6 deficiency resulted in increased oxidative 
stress, decreased cell survival, and delayed wound healing (Penkowa et al., 2000; 
Penkowa et al., 2003; Ziebell and Morganti-Kossmann, 2010).  
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In addition to cytokines, expression of neurotrophins and other growth factors are 
also modulated following CNS injury (Nieto-Sampedro et al., 1982; Hicks et al., 1997; 
Ghirnikar et al., 1998; Hicks et al., 1999; Lee et al., 2002; Lai and Todd, 2006).  
Neurotrophins, such as BDNF, nerve growth factor (NGF), and neurotrophin-3 (NT-3), 
are produced in the CNS by microglia, astrocytes, and neurons, and promote cell 
survival, growth, and differentiation effects by activating intracellular signal 
transduction pathways through interactions with specific high-affinity tyrosine kinase 
(trk) receptors (Meakin and Shooter, 1992; Barbacid, 1994; Elkabes et al., 1996; Miwa 
et al., 1997; Ghirnikar et al., 1998; Skaper and Walsh, 1998; Hicks et al., 1999).  
Although BDNF, the most abundantly expressed neurotrophin in the mature CNS (Hofer 
et al., 1990), has been shown to be neuroprotective in animal models of excitotoxicity, 
axotomy, and ischemia (Yan et al., 1992; Kindy, 1993; Beck et al., 1994; Cheng and 
Mattson, 1994; Tsukahara et al., 1994; Schabitz et al., 1997), neuroprotection does not 
appear to occur following TBI (Blaha et al., 2000).  Conversely, NGF attenuated 
neuronal death in both TBI and ischemia (Shigeno et al., 1991; Sinson et al., 1995), 
suggesting that different types of CNS injury may require a specific compliment of 
neurotrophins to attenuate tissue damage and improve functional outcomes.   Other 
growth factors produced by microglia also play a prominent role following CNS 
damage, such as transforming growth factor-beta (TGFβ) (Wiessner et al., 1993; 
Lehrmann et al., 1998; Zhu et al., 2000), basic fibroblast growth factor (bFGF; Shimojo 
et al., 1991; Li and Stephenson, 2002; Lai and Todd, 2006), and IGF-1 (Sandberg 
Nordqvist et al., 1996; Beilharz et al., 1998; Wildburger et al., 2001; Hwang et al., 2004; 
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Madathil et al., 2010).  In particular, IGF-1 promotes neuronal survival, neurite 
outgrowth, maturation of oligodendrocytes, and myelination in the brain (D'Ercole et al., 
1996), and it has neuroprotective effects after ischemic stroke and TBI (Lai and Todd, 
2006; Madathil et al., 2010).  Specifically, administration of IGF-1 reduced neuronal 
loss and infarct volume and increases glial proliferation following cerebral ischemia 
(Loddick and Rothwell, 1996; Guan et al., 2001; Liu et al., 2001; Cao et al., 2003), and 
both increased BDNF and NT-3 levels and improved motor and cognitive function after 
TBI (Kazanis et al., 2004; Saatman et al., 2006).  Given that BDNF and IGF-1 are 
induced in both microglia and neurons following CNS injury and are functionally 
divergent from similarly microglia-derived pro-inflammatory cytokines like IL-1β and 
TNF-α (Hicks et al., 1999; Lee et al., 2002; Hwang et al., 2004; Lai and Todd, 2006; 
Jordan et al., 2008; Madathil et al., 2010; Ziebell and Morganti-Kossmann, 2010), 
optimizing therapeutic strategies for brain injury will require careful modulation of the 
microglia-activated balance between negating the detrimental effects of pro-
inflammatory cytokine induction and maintaining the neuroprotection afforded by 
likewise induced growth factors.  
Similar to ischemic stroke and TBI, maintenance of the blood-spinal cord barrier 
is necessary to ensure proper functionality of spinal nerve cells, glial cells, and axons, 
and dysregulation of the blood-spinal cord barrier following traumatic injury is critical to 
the development of spinal cord pathology and sensory-motor disruptions (Noble and 
Wrathall, 1989; Bilgen et al., 2002; Pan and Kastin, 2008; Sharma, 2008, 2011).  
Specifically, edema formation is an important driver of SCI pathology (Sharma, 2008, 
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2011), prominent within 2-5 min of injury and present as long as 15 days post-SCI 
(Nolan, 1969; Demediuk et al., 1987), dependent on the severity of the contusion injury 
(Noble and Wrathall, 1988, 1989; Sharma, 2005a, b), and associated with tissue damage 
at the lesion site (Schwab and Bartholdi, 1996; Sharma, 2011).   Furthermore, inhibition 
of blood-spinal cord barrier disruption results in substantial neuroprotection (Sharma et 
al., 1993a, b; Sharma et al., 1993c; Sharma et al., 1995).  Initiation of neuroinflammation 
by activated microglia additionally contributes to injury pathology, resulting in the 
axonal injury, demyelination, and delayed neuronal and glial cell death that drives 
secondary degeneration, and their inhibition reduces secondary injury (Giulian and 
Robertson, 1990; Blight, 1994; Popovich et al., 2002; Gomes-Leal et al., 2004).  
Activated microglia modulate astrogliosis (Ridet et al., 1997; Fitch et al., 1999) and 
produce pro-inflammatory cytokines, including IL-1β, IL-6, and TNF-α, which 
contribute to activation of astrocytes and other nearby microglia (Bartholdi and Schwab, 
1997; Streit et al., 1998; Okada et al., 2004; Nakamura et al., 2005; Gris et al., 2007; 
Karimi-Abdolrezaee and Billakanti, 2012).   
IL-1β induces astrocytic production of IL-6 and TNF-α as well as itself in a 
positive feedback loop (Chung and Benveniste, 1990; Norris et al., 1994; Wang et al., 
2006), and treatment of contused spinal cord with IL-1 receptor antagonist at the lesion 
site has been shown to attenuate contusion-induced apoptosis (Nesic et al., 2001).  
However, IL-1β mediated activation of astrocytes also has several beneficial effects on 
the CNS microenvironment following injury, as it stimulates production of 
neuroprotective trophic and growth factors, such as fibroblast growth factor-2 (FGF-2), 
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NGF, and IGF-1, and contributes towards restoration of the blood-spinal cord barrier 
(Brenneman et al., 1995; Fitch et al., 1999; Mason et al., 2001; Albrecht et al., 2002; 
Liberto et al., 2004; Sofroniew, 2005; Wang et al., 2006; Sofroniew, 2009).  Similarly, 
studies have shown dual neuroprotective and cytotoxic roles for TNF-α, where inhibition 
of TNF-α resulted in significantly improved functional recovery and reduction in blood-
spinal cord barrier dysfunction and edema formation (Bethea et al., 1999; Bethea and 
Dietrich, 2002; Sharma et al., 2003; Sharma, 2010), but removal of TNF receptors 
reduced functional recovery and increased both apoptosis and lesion size due to a 
reduction in activation of the nuclear factor-kappaB (NF-kB) signaling pathway that led 
to an increase in the active form of the caspase-3 protein  (Kim et al., 2001).  The NF-kB 
transcription factor is a major regulator of immune and inflammatory responses, and its 
activation by TNF-α, along with IL-1β, drives astrogliosis following CNS injury 
(Yamamoto and Gaynor, 2001; Li and Verma, 2002; Zhang et al., 2009).  Interestingly, 
selective inactivation of NF-kB in astrocytes is neuroprotective, resulting in dramatic 
improvement in functional recovery, reduced lesion volume, increased white matter 
sparing, and substantially decreased expression of pro-inflammatory cytokines and glial 
scar proteins (Brambilla et al., 2005).  Because NF-kB activation in astrocytes also 
induces production of BDNF and NGF and ablation of reactive astrocytes compromises 
the reconstruction of the blood-spinal cord barrier after SCI (Zaheer et al., 2001; 
Faulkner et al., 2004), it is possible that the damaging effects incurred by removal of 
TNF receptors may be a result of the complete loss of both TNF and NF-kB signaling 
overly inhibiting astrogliosis, resulting in suppression of the beneficial production of 
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neurotrophins in both NF-kB-dependent and independent pathways and prevention of 
reactive astrocyte-mediated restoration of neurovascular integrity (Liberto et al., 2004; 
Zhang et al., 2009; Karimi-Abdolrezaee and Billakanti, 2012).  While reactive astrocyte-
mediated reconstruction of the blood-spinal cord barrier is essential for SCI repair (Fitch 
et al., 1999; Sofroniew, 2005, 2009; Karimi-Abdolrezaee and Billakanti, 2012), glial 
scar formation poses both physical and chemical barriers to axonal regeneration 
(McKeon et al., 1995; Silver and Miller, 2004; Busch and Silver, 2007) and prevents 
differentiation of both adult neuronal and oligodendrocyte precursor cells (Horky et al., 
2006; Karimi-Abdolrezaee et al., 2006; Barnabe-Heider and Frisen, 2008; Karimi-
Abdolrezaee et al., 2010; Siebert and Osterhout, 2011; Siebert et al., 2011).  
Correspondingly, induction of IL-6 in reactive astrocytes promotes production of glial 
scar proteins and a corresponding increase in glial scarring (Nakamura et al., 2005; Gris 
et al., 2007), while administration of anti-IL-6 antibodies attenuates glial scar formation, 
suppresses secondary injury through inhibition of neuroinflammation, and improves 
functional recovery (Okada et al., 2004). 
Microglia and astrocyte activation also modulates expression of neurotrophins 
and growth factors following spinal cord trauma (Schwab and Bartholdi, 1996; Liberto 
et al., 2004; Sharma, 2005a, b, 2007a, 2011; Karimi-Abdolrezaee and Billakanti, 2012). 
Specifically, although expression of BDNF and IGF-1 is reduced at the lesion site during 
the early phases of SCI, both play an important role in injury pathology and exhibit 
therapeutic potential (Sharma et al., 1997; Sharma et al., 1998; Sharma et al., 2000a; 
Sharma et al., 2000b; Sharma, 2007a, 2011).  Expression of both trkB and trkC receptors 
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is increased in neurons and astrocytes at the lesion site (Frisen et al., 1992), and BDNF, 
along with NT-3, is up-regulated in motor neurons and astrocytes rostral to the lesion 
(Uchida et al., 1998), suggesting that changes in BDNF/trkB signaling intensity and 
sensitivity varies spatially after SCI.  In addition, IL-1β induced expression of IGF-1 in 
astrocytes is important for terminal differentiation of oligodendrocytes precursors and 
subsequent remyelination of axons following injury, and inhibited astrogliosis due to a 
lack of IL-1β signaling significantly impairs remyelination (Mason et al., 2001; Liberto 
et al., 2004).  Furthermore, application of BDNF or IGF-1, either alone or in 
combination, within 30 min of SCI has been shown to significantly reduce blood-spinal 
cord barrier disruption, edema formation, NOS regulation, lesion size, and cell death 
(Novikova et al., 1996; Sharma et al., 1997; Jakeman et al., 1998; Sharma et al., 1998; 
Sharma, 2005a, b, 2006, 2007a, b, 2011).  While these results are promising, the 
multifaceted state of the spinal cord microenvironment following traumatic injury 
suggests that more sophisticated therapeutic approaches may be needed to effectively 
coordinate inhibition of neuroinflammation and glial scar formation, rapid restoration of 
the blood-spinal cord barrier, and induction of trophic support in order to minimize 
secondary injury, promote regeneration, and facilitate robust functional recovery in 
human SCI patients. 
 
1.2 Neuropathic Pain 
Spinal cord injury can result in severely debilitating consequences, including loss of 
motor control, paralysis, and neuropathic pain.  Chronic pain affects approximately two-
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thirds of all SCI patients and can arise from nerve damage suffered with a concomitant 
peripheral tissue injury, in addition to damage to the spinal cord itself (Siddall and 
Loeser, 2001).  Peripheral damage induces maladaptive spinal cord plasticity, consisting 
of sensitization of spinal neurons (Woolf and Wall, 1986; Sluka et al., 1997; Hains et al., 
2003; Lampert et al., 2006), increased glial activity (Frei et al., 2000; Hains and 
Waxman, 2006; Detloff et al., 2008), and induced excitotoxicity and cell death (Liu et 
al., 1999; Beattie et al., 2002; Xu et al., 2004; Kuzhandaivel et al., 2011), by acting on 
nociceptive fibers as an uncontrollable source of over-excitation (Christensen and 
Hulsebosch, 1997; Ji et al., 2003; Yang et al., 2004), leading to development of 
neuropathic pain.  In addition, uncontrollable nociceptive stimulation can severely 
undermine recovery of motor and sensory function.  In adult rats, just 6 min of 
intermittent noxious stimulation impaired locomotor recovery, increased tissue loss, 
delayed the recovery of bladder function, and led to greater mortality and spasticity 
(Grau et al., 2004).  Furthermore, whereas controllable stimulation promotes spinal 
learning (Crown et al., 2002), uncontrollable nociception inhibits adaptive spinal 
plasticity and increases allodynia (Ferguson et al., 2006).  Intermittent noxious 
stimulation appears to mediate spinal plasticity mostly through down-regulation of 
BDNF and trkB (Gomez-Pinilla et al., 2007; Garraway et al., 2011), which cooperatively 
play an important role in modulation of neuronal plasticity, induction of axonal 
regeneration, and promotion of functional recovery following SCI (Xu et al., 1995; 
Patterson et al., 1996; McTigue et al., 1998; Kerr et al., 1999; Garraway et al., 2003; 
Boyce et al., 2007).  Consequently, direct application of exogenous BDNF to the spinal 
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cord following injury could attenuate both uncontrollable nociception-induced 
maladaptive spinal plasticity and subsequent neuropathic pain symptoms.   
One of the five first-line and most effective pharmalogical treatments for chronic 
pain after SCI is administration of opiate analgesics, such as morphine, with 
approximately one-third (33.3%) of all patients prescribed opiates reporting considerable 
improvement or elimination of pain (Dworkin et al., 2003; Widerstrom-Noga and Turk, 
2003; McCarberg, 2004).  While it was hypothesized that morphine could block the 
adverse effects of uncontrollable nociceptive stimulation applied below the level of 
injury, not only were these effects not attenuated, but a single dose of systemic morphine 
given on the day after spinal cord contusion exacerbated the effects of uncontrollable 
nociception, and rats treated with morphine and uncontrollable tailshock had a higher 
rate of mortality and displayed allodynic responses to innocuous sensory stimuli 3 weeks 
later (Hook et al., 2007).  In addition, morphine treatment undermined recovery of 
sensory function and increased lesion size, independent of uncontrolled shock exposure.   
Similarly, administration of intrathecal morphine 24 hrs after contusion injury 
significantly attenuated the recovery of locomotor function, increased lesion size, 
decreased weight gain, and substantially increased mortality and autophagia (Hook et al., 
2009).  Morphine induced development of paradoxical pain symptoms has been 
attributed to immune responses (Watkins et al., 2005; Scholz and Woolf, 2007; Watkins 
et al., 2007), and prolonged morphine administration has been shown to activate 
microglia and astrocytes, leading to up-regulation of the pro-inflammatory cytokines IL-
1β, IL-6, and TNF-α that block the analgesic effects of opioids (Gul et al., 2000; Song 
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and Zhao, 2001; Raghavendra et al., 2002; Szabo et al., 2002; Johnston et al., 2004; Cui 
et al., 2006; Tai et al., 2006).  In particular, IL-1β has been shown to regulate a number 
of processes that propagate neuroexcitability and spinal sensitization, which in turn 
increases pain reactivity (Inoue et al., 1999; Viviani et al., 2003; Stellwagen et al., 2005; 
Tai et al., 2006; Prow and Irani, 2008).  Furthermore, increased expression of IL-1β 
following morphine exposure, along with TNF-α, may exacerbate secondary injury by 
up-regulating expression of cytotoxic factors, such as inducible form of nitric oxide 
synthase, through activation of the astrocytic NF-kB pathway (Conti et al., 2007).  
Indeed, application of IL-1 receptor antagonist blocked the adverse effects of morphine 
on locomotor recovery and neuropathic pain (Hook et al., 2011).  However, 
administration of the IL-1ra alone undermined functional recovery and increased tissue 
loss at the lesion site, suggesting that management of neuropathic pain and mitigation of 
morphine tolerance will require a more comprehensive and balanced approach to 
beneficially modulate microglia and astrocyte activation, production of pro-
inflammatory cytokines, and regulation of neurotrophic signaling. 
 
1.3 MicroRNA Overview and Dysregulation in CNS Injury 
Effective therapeutic strategies that are capable of substantially improving functional 
outcomes and minimizing the impact of SCI by reducing cell death in the injury zone, 
promoting regeneration, and inhibiting the maladaptive spinal plasticity that drives 
neuropathic pain will require coordinated regulation of complex gene networks that 
mediate blood-spinal cord barrier disruption, activation of microglia and astrocyte, 
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induction of pro and anti-inflammatory cytokines, and glial scar formation.  While 
altered gene expression has been shown to significantly contribute towards the 
pathogenesis of secondary SCI (Nesic et al., 2002; Bareyre and Schwab, 2003; De Biase 
et al., 2005), there is limited knowledge of regulatory networks that coordinate and 
control gene expression.  MicroRNAs (miRNAs) are short, 18 to 25 nucleotide-long 
non-coding small RNAs that regulate gene expression by inhibiting protein translation or 
targeting mRNA transcripts for degradation (Alvarez-Garcia and Miska, 2005; Zamore 
and Haley, 2005).  Individual miRNAs can simultaneously regulate several hundred 
mRNAs to affect specific biological processes related to cellular differentiation, growth, 
and apoptosis, as well as metabolic, immune, and inflammatory responses (Alvarez-
Garcia and Miska, 2005; Stefani and Slack, 2008; Breving and Esquela-Kerscher, 2010).   
 MiRNA biogenesis begins in the nucleus with the transcription of miRNA genes, 
located in intergenic regions as well as in introns and exons of other genes, by 
Polymerase II, which yields a pri-miRNA precursor averaging hundreds to thousands of 
nucleotides in length (He and Hannon, 2004; Figure 1.1; Filipowicz et al., 2008; Breving 
and Esquela-Kerscher, 2010).  In mammals, these pri-miRNAs are then processed by the 
Drosha-DGCR8 complex, consisting of the RNase-III type endonuclease Drosha and 
DiGeorge syndrome critical region gene 8 (DGCR8) protein, which recognizes stem-
looped secondary structures of the pri-miRNA and excises them into approximately 70 
nucleotide long, hairpin-shaped pre-miRNA precursors (Du and Zamore, 2005; Bushati 
and Cohen, 2007; Peters and Meister, 2007; Rana, 2007; Filipowicz et al., 2008).  Pre-
miRNAs are then exported out of the nucleus to the cytoplasm by exportin-5 and cleaved 
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by the endoribonuclease Dicer, complexed with TAR RNA binding protein (TRBP), to 
yield ~20 nucleotide miRNA duplexes.  Typically, one strand is then selected to function 
as the mature miRNA, while the other is degraded, although occasionally both strands of 
the pre-miRNA become mature miRNAs (Du and Zamore, 2005; Bushati and Cohen, 
2007; Peters and Meister, 2007; Rana, 2007; Filipowicz et al., 2008).  Mature miRNAs 
are finally loaded onto miRNA-induced silencing complexes (miRISCs), of which 
Argonaute proteins play a key role.  In animals, miRNAs interact with the 3’ UTR of 
their target mRNAs through imperfect base pairing and according to experimentally and 
bioinformatically identified rules, with few exceptions (Doench and Sharp, 2004; 
Brennecke et al., 2005; Lewis et al., 2005; Grimson et al., 2007; Nielsen et al., 2007; 
Filipowicz et al., 2008).  MiRNA-target base pairing must be perfect and contiguous for 
miRNA nucleotides 2 to 8 of the seed region to nucleate miRNA-mRNA association and 
establish efficient repression, base mismatches or bulges must be present in the central 
region of the miRNA-mRNA duplex, and there must be acceptable complementarity to 
the 3’ end of the miRNA to stabilize the reaction (Brennecke et al., 2005; Grimson et al., 
2007).  In addition, multiple copies of miRNA binding sites are usually present in the 
target 3’ UTR, and multiple sites for the same or different miRNAs are typically 
required for effective repression (Doench and Sharp, 2004; Brennecke et al., 2005; 
Lewis et al., 2005; Grimson et al., 2007; Nielsen et al., 2007; Filipowicz et al., 2008).  
Multiple binding sites can also synergistically when within 10-40 nucleotides of each 
other to enhance repression beyond their combined individual effects (Doench and 
Sharp, 2004; Grimson et al., 2007).    
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Figure 1.  Schematic for the biogenesis of miRNAs.  MiRNA genes are first transcribed in the nucleus by 
RNA Polymerase III into a pri-miRNA before the Drosha/DGCR8 complex processes them into ~70 
nucleotide long pre-miRNAs.  Pre-miRNAs are then transported from the nucleus into the cytoplasm by 
Exportin 5 and further processed into double stranded miRNA-miRNA* duplexes by the Dicer complex.  
Once the two duplex strands are separated, mature miRNA guide strands are preferentially loaded onto the 
RNA-induced silencing complex (RISC), and the assembled miRNA-RISC complex then targets 
complimentary seed regions of mRNA 3’UTRs for either suppression of translation or mRNA 
degradation. 
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 MicroRNAs have been shown to be dysregulated in the CNS following stroke 
and traumatic brain injury (Lei et al., 2009; Redell et al., 2010; Saugstad, 2010; Liu et 
al., 2011; Rink and Khanna, 2011; Tan et al., 2011).  Transient focal ischemia in adult 
rat brain results in dysregulation of 20 miRNAs predicted to target mRNAs known to 
mediate transcription, ionic homeostasis, neuroprotection, and inflammation (Dharap et 
al., 2009; Saugstad, 2010).  Interestingly, miR146a, an anti-inflammatory miRNA that 
targets IL-6 and interleukin-1 receptor associated kinase-1 (IRAK-1), has exhibited 
biphasic expression following cerebral ischemia with acute down-regulation followed by 
substantial induction at 7 days following injury (Taganov et al., 2006; Bhaumik et al., 
2009; Liu et al., 2010; Liu et al., 2011; Tan et al., 2011).  In addition, expression of 
miR124a, a key promoter of neuronal differentiation, was significantly decreased in 
neural progenitor cells within the subventricular zone following focal cerebral ischemia 
(Liu et al., 2011).  Similarly, robust miRNA dysregulation is observed following 
traumatic brain injury, and predicted targets of impacted miRNAs include proteins of 
signaling pathways induced by injury, including signal transduction, transcriptional 
regulation, proliferation, and differentiation (Redell et al., 2009; Saugstad, 2010).  Of 
particular note, miR21 exhibits substantial transient up-regulation with peak expression 
approximately 3 days after TBI (Lei et al., 2009; Redell et al., 2011).  As miR21 is 
known to be strongly anti-apoptotic and induce proliferation (Sathyan et al., 2007), it is 
possible that it plays an important role in the progression of neuroinflammation. 
 MicroRNAs are also dysregulated following spinal cord trauma (Liu et al., 2009; 
Nakanishi et al., 2010; Strickland et al., 2011; Yunta et al., 2012).  Initial reports 
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indicated a time-dependent dysregulation of a number of miRNAs implicated in the 
inflammation, oxidation, and apoptosis that contribute towards the pathogenesis of SCI 
(Liu et al., 2009; Nakanishi et al., 2010).  As will be discussed in detail in Section 2, we 
identified a subset of miRNAs, including brain trauma-sensitive miR124, miR21, and 
miR146a, that were significantly dysregulated following SCI and exhibited specific, 
coordinated changes in temporal and spatial expression patterns (Strickland et al., 2011).  
Because miR124 suppresses activation of microglia prior to SCI and both miR21 and 
miR146a are able to inhibit astrogliosis following injury (Ponomarev et al., 2011; 
Bhalala et al., 2012; Iyer et al., 2012; Willemen et al., 2012), dysregulation of these 
miRNAs, along with other SCI-sensitive miRNAs, may play an important role in 
mediating neuroinflammation, secondary injury, and neuropathic pain following spinal 
cord contusion. 
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2. MICRORNA DYSREGULATION FOLLOWING SPINAL CORD CONTUSION: 
IMPLICATIONS FOR NEURAL PLASTICITY AND REPAIR* 
 
2.1 Overview 
Spinal cord injury (SCI) is medically and socioeconomically debilitating.  Currently, 
there is a paucity of effective therapies that promote regeneration at the injury site, and 
limited understanding of mechanisms that can be utilized to therapeutically manipulate 
spinal cord plasticity.  MicroRNAs (miRNAs) constitute novel targets for therapeutic 
intervention to promote repair and regeneration.  Microarray comparisons of the injury 
sites of contused and sham rat spinal cords, harvested 4 and 14 days following SCI, 
showed that 32 miRNAs, including miR124, miR129, and miR1, were significantly 
down-regulated, whereas SNORD2, a translation-initiation factor, was induced.  
Additionally, 3 miRNAs including miR21 were significantly induced, indicating 
adaptive induction of an anti-apoptotic response in the injured cord.  Validation of 
miRNA expression by qRT-PCR and in situ hybridization assays revealed that the 
influence of SCI on miRNA expression persists up to 14 days and expands both 
anteriorly and caudally beyond the lesion site.  Specifically, changes in miR129-2 and 
miR146a expression significantly explained the variability in initial injury severity, 
suggesting that these specific miRNAs may serve as biomarkers and therapeutic targets  
________________________________________ 
*Reprinted with permission from “MicroRNA Dysregulation Following Spinal Cord Contusion: 
Implications for Neural Plasticity and Repair” by E.R. Strickland, M.A. Hook, S. Balaraman, J.R. Huie, 
J.W. Grau, and R.C. Miranda, 2011.  Neuroscience, 186, 146-160, Copyright 2011 by Elsevier. 
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for SCI.  Moreover, the pattern of miRNA changes coincided spatially and temporally 
with the appearance of SOX2, nestin, and REST immunoreactivity, suggesting that 
aberrant expression of these miRNAs may not only reflect the emergence of stem cell 
niches, but also the reemergence in surviving neurons of a pre-neuronal phenotype.  
Finally, bioinformatics analysis of validated miRNA-targeted genes indicates that 
miRNA dysregulation may explain apoptosis susceptibility and aberrant cell cycle 
associated with a loss of neuronal identity, which underlies the pathogenesis of 
secondary SCI. 
 
2.2 Introduction 
Current understanding of the mechanisms underlying spinal cord injury (SCI) is limited, 
and traditional therapeutic methods lack a molecular approach to prevent the loss of 
sensory function and paralysis.  Effective rehabilitation will require a multifaceted 
therapeutic strategy that promotes tissue regeneration, reduces cell death in the 
secondary injury zone, and improves native function through behavioral training.  To 
accomplish this, it is imperative to uncover the upstream genetic regulators responsible 
for coordinating the acute inflammatory and apoptotic responses driving secondary 
spinal cord injury, in addition to the chronic inflammation resulting from uncontrollable 
nociceptive stimulation, that impairs functional recovery through reduction of spinal 
cord plasticity (Grau et al., 2004; Grau et al., 2006; Hook et al., 2009).  Therapeutic 
manipulation of these mechanisms, as well as other novel genetic and biochemical 
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pathways, could represent effective treatments for improving functional recovery, 
minimizing pathological damage, and attenuating neuropathic pain. 
Other investigators have previously reported that altered gene expression 
significantly contributes to the pathogenesis of secondary SCI (Nesic et al., 2002; 
Bareyre and Schwab, 2003; De Biase et al., 2005), but there is limited knowledge of the 
regulatory networks that control gene expression.  MiRNAs are short, ~22 nucleotide 
non-coding small RNAs that regulate gene expression by controlling protein translation 
or destabilizing mRNA transcripts (Alvarez-Garcia and Miska, 2005; Zamore and Haley, 
2005).  Individual miRNAs coordinate the expression of several hundred protein-coding 
genes, to affect a specific biological endpoint.  In addition, many miRNAs exhibit 
remarkable phylogenetic similarities, and often complete evolutionary conservation (Lee 
et al., 2007), which is ideal for studying their effects and clinical relevance in animal 
models, such as Rattus norvegicus.  Consequently, miRNAs may constitute one 
therapeutic target to alter the cellular proteome in the damaged spinal cord, to promote 
repair and regeneration.  Initial reports on miRNA dysregulation following SCI have 
outlined expression changes in numerous miRNAs at time points ranging from 1 hr to 7 
days; however, these analyses were strictly limited to the injury site, primarily focused 
on inflammatory and apoptotic mediated changes that dominate the early response to 
injury, and only reported localization patterns for miR124a and miR223 (Liu et al., 
2009; Nakanishi et al., 2010).   
The current study focused on a time course ranging from 24 hours to 14 days 
post-SCI, to evaluate the relationship between miRNA expression and functional 
  
 
24 
recovery following trauma.  We also examined miRNA changes both rostral and caudal 
to the injury site, as significant changes in rostral/caudal gene expression have also been 
observed in response to a spinal cord contusion (De Biase et al., 2005).  Likewise, we 
analyzed the functional roles of genes known to be regulated by significant miRNAs to 
determine the possible global effects of SCI-mediated miRNA dysregulation.  Finally, 
we investigated the temporal relationship between miRNA profiles and expression 
patterns of biomarkers that indicate reemerging plasticity and loss of cellular identity 
following SCI. 
 
2.3 Experimental Procedures 
2.3.1 Subjects 
The subjects were male Sprague–Dawley rats (Rattus norvegicus) obtained from Harlan 
(Houston, TX). The rats were approximately 90-110 days old (300-350 g), and were 
individually housed in Plexiglas bins [45.7 (length) x 23.5 (width) x 20.3 (height) cm] 
with food and water continuously available.  To facilitate access to the food and water, 
extra bedding was added to the bins after surgery and long mouse sipper tubes were used 
so that the rats could reach the water without rearing.  Bladders were manually expressed 
in the morning (8-9:30 a.m.) and evening (6-7:30 p.m.) until subjects regained bladder 
control, which was operationally defined as three consecutive days with an empty 
bladder at the time of expression.  Rats were maintained on a 12-hr light/dark cycle.  All 
procedures described in these experiments were reviewed and approved by the Texas 
A&M University Laboratory Animal Care Committee. 
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2.3.2 Surgery 
Subjects received a contusion injury using the Multicenter Animal Spinal Cord Injury 
Study (MASCIS) Impactor device (Gruner, 1992; Constantini and Young, 1994).  
Subjects were anesthetized with isoflurane (5%, gas).  Once a stable level of anesthesia 
was achieved the inspired concentration of isoflurane was lowered to 2-3% and an area 
extending approximately 4.5 cm above and below the injury site was shaved and 
disinfected with iodine.  A 7.0 cm incision was made over the spinal cord.  Next, two 
incisions were made on either side of the vertebral column, extending about 3 cm rostral 
and caudal to the T12-T13 segment.  The dorsal spinous processes at T12-T13 were 
removed (laminectomy), and the spinal tissue exposed.  The dura remained intact.  The 
vertebral column was fixed within the MASCIS device, and a moderate injury was 
produced by allowing the 10-g impactor (outfitted with a 2.5 mm tip) to drop 12.5 mm.  
T12-T13 level contusion models have been routinely used by members of our group to 
define spinal cord learning circuits and molecular mechanisms involved with recovery of 
function (e.g., (Ferguson et al., 2008; Brown et al., 2011; Hook et al., 2011)).  Lesions at 
this level result in well-defined and replicable sensory-motor deficits, and we therefore 
chose to utilize contusion at this level to also examine changes in miRNA expression.  
Contusions at the T12-T13 level resulted in mean BBB (Basso, Beattie, and Bresnahan 
scale (Basso et al., 1995)) score of 2.75 +/- 0.49 (mean +/- SEM), indicating significant 
loss of locomotor function.  There were no statistically significant differences in BBB 
scores between the various contusion groups.  Sham controls received a laminectomy, 
but the cord was not contused with the MASCIS device.  Following surgery, the wound 
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was closed using Michel clips.  To help prevent infection, subjects were treated with 
100,000 units/kg Pfizerpen (penicillin G potassium) immediately after surgery and again 
2 days later.  For the first 24 hours after surgery, rats were placed in a recovery room 
maintained at 26.6 °C.  To compensate for fluid loss, subjects were given 2.5 ml of 
saline after surgery. Subjects were given about 20-24 hr to recover from surgery, and 
during recovery, additional saline was given to maintain hydration. 
 
2.3.3 Assessment of locomotor function 
Locomotor behavior was assessed for up to 14 days post-surgery using the BBB scale in 
an open enclosure (99 cm in diameter, 23 cm deep).  Baseline motor function was 
assessed on the day following surgery.  Because rodents often remain motionless 
(freeze) when introduced to a new apparatus, subjects were acclimated to the observation 
fields for 5 min per day, for 3 days prior to surgery.  Each subject was placed in the open 
field, observed for 4 min, and scored for locomotor behavior using the procedure 
developed by Basso et al. (1995).  Care was taken to ensure that the investigators’ 
scoring behavior had high intra- and inter- observer reliability (all r’s > 0.89), and that 
they were blind to the subject’s experimental treatment. 
 
2.3.4 Isolation of RNA for microarray and qRT-PCR quantification 
Subjects were anesthetized 24 hrs, 4 days, or 14 days after injury and a 1 cm long 
segment of the spinal cord from the lesion center, as well as 1 cm rostral and caudal to 
the injury epicenter, was removed and flash-frozen in liquid nitrogen.  Specimens were 
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crushed and RNA was isolated using the TRIzol (Invitrogen; Carlsbad, CA) protocol.  
MiRNA was then quantified using a Bioanalyzer 2100 (Agilent Technologies; Carmel, 
IN) and stored at -80 °C. 
 
2.3.5 MiRNA labeling and hybridization 
MiRNA expression of contused and sham spinal cords were compared using dual 
channel arrays on a HS 400 Pro hybridization platform (TECAN; Research Triangle 
Park, NC).  Extracted miRNA from all sham controls were pooled in equal 
concentrations to eliminate outliers from control expression, and compared to each 
contused and sham sample individually.  Dye swapping was utilized to eliminate bias, 
and a total of 12 arrays were hybridized according to the EXIQON miRCURYTM locked 
nucleic acid (LNA) microRNA Array Power Labeling kit protocol.  After hybridization, 
arrays were scanned using a GenePix 400B scanner (Molecular Devices; Union City, 
CA), and the scanner gain and sensitivity was set so that the overall ratio of Cy3 to Cy5 
intensity across the array was set at 1.  Array features that were irrelevant to the analysis 
such as blank spots, Cy3 control features, and miRNA features for all species except rat, 
human, and mouse, were removed before statistical analyses.  Data were exported to and 
analyzed for significance using GeneSifter software (Geospiza; Seattle, WA).  
Significantly expressed miRNAs were grouped according to fold change in expression 
and by genome clustering.  
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2.3.6 Quantitative RT-PCR for miRNA 
Microarray data was validated with quantitative reverse transcription (qRT)-PCR for 
miRNAs, based on the protocol of the miRCURYTM LNA microRNA Universal RT-
PCR system (EXIQON; Woburn, MA).  RNA samples were converted to cDNA, and 
qRT-PCR was performed using a MyiQTM Single-Color Real-Time PCR Detection 
System (Bio-Rad, Hercules, CA).  Forward and reverse primers (EXIQON; Woburn, 
MA) for hsa-miR124, hsa-miR223, hsa-miR1, hsa-miR21, hsa-miR129-2, hsa-miR129-
1, and hsa-miR146a, were used for PCR amplification, and real time data was 
normalized using U6 RNA.  Relative miRNA expression was determined by calculating 
the mean difference between cycle threshold of the miRNA from the U6 small nuclear 
RNA (U6SNB) normalized control for each sample [Δ cycle threshold (ΔCT)] within each 
sample group (samples with same miRNA ID, time, and condition parameters) and 
expressed as -ΔCT for relative change in expression.  Sample means that were greater 
than ± 2 standard deviations from the mean ΔCT, or ± 3 standard deviations from the 
mean ΔCT after exclusion, were considered outliers and removed from the analysis.  Of 
the 425 data points in 84 groups used in the analysis, only 17 data points were excluded 
according to this criteria, and no more than one data point in any individual experimental 
group was excluded.  Fold change in miRNA expression was determined by calculating 
the difference between the mean ΔCTs of contused and sham sample groups at the same 
time point and spinal cord location (ΔΔCT), and expressed as fold-change (2-ΔΔCT). 
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2.3.7 In situ hybridization & immunofluorescence analyses 
For immunofluorescence and in situ hybridization analyses, 24 hrs, 4 days or 14 days 
after injury subjects were deeply anesthetized with pentobarbital (100 mg/kg, i.p.), and 
perfused (intracardially) with 4% paraformaldehyde in 0.1 M saline buffer.  A 1 cm long 
segment of the spinal cord was taken from the lesion center, as well as 1 cm rostral and 
caudal to the injury epicenter, and prepared for cryostat sectioning.  The tissue was then 
sectioned to a thickness of 30 microns, in either a longitudinal or coronal orientation, 
and mounted onto suprafrost plus slides (VWR Scientific; West Chester, CA).  In situ 
hybridization was conducted using biotin labeled LNA-modified oligonucleotide probes 
(EXIQON; Woburn, MA) according to the EXIQON instructions, followed by 
incubation with rhodamine avidin D for 1 hour at 4 °C.  Slides were mounted and 
nuclear stained using VectaShield mounting medium with DAPI (Vector Labs; 
Burlingame, CA).  Immunofluorescence was performed according to standard 
methodologies using monoclonal mouse anti-nestin, and polyclonal rabbit antibodies for 
glial fibrillary acidic protein (GFAP), RE1-silencing transcription factor (REST), sex 
determining region Y-box 2 (SOX2), and neurofilament (Abcam; Boston, MA).  The 
secondary antibodies utilized included goat anti-mouse Alexafluor® 488 and goat anti-
rabbit Alexafluor® 594 (Invitrogen; Eugene, CA).  All primary and secondary antibodies 
were used at 1:200 and 1:300 dilutions, respectively. All photomicrography was 
conducted using an Olympus FSX100 microscope with imaging software (FSX-BSW 
v.2.01, Olympus), or on an Olympus BX60 microscope. 
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2.3.8 Data analyses 
Microarray-derived data were analyzed by t-tests with Benjamini and Hochberg FDR 
corrections for multiple comparisons, using GeneSifter (Geospiza; Seattle, WA).  All 
other data were analyzed using SPSS software version 18 (SPSS; Chicago, IL).  
MicroRNA expression, verified by qRT-PCR, was analyzed by multivariate analysis of 
variance (ANOVA) using Pillai’s trace statistic, and further analyzed using post hoc 
univariate ANOVA and Fisher’s least significant difference (f-LSD) test.  Other data 
were analyzed using ANOVAs followed by post hoc f-LSD using planned comparisons.  
In all cases, the priori α value was set at 0.05.  Data were expressed as mean ±SEM, as 
indicated in the figure legends.  
 The statistical relationship between injury severity and change in miRNA 
expression after SCI (the R2, a goodness of fit) was determined using least squares 
regression analysis of explained variance, with BBB score at 24 hrs after surgery as the 
independent variable, and difference in cycle threshold change (-ΔΔCT; between 
contused subjects at 4 and up to 14 days post-SCI, and the mean of sham controls) as the 
dependent variable.  Correlations between pairings of miRNAs were determined by 
Pearson’s product-moment correlation (PPMC) using –ΔΔCT values of the paired 
miRNAs at 4 days post-SCI as separate independent variables.  The priori α value was 
set at 0.05, and data were expressed as the difference in cycle threshold change of each 
contused subject relative to the mean cycle threshold change of sham controls (-ΔΔCT= 
ΔCT sham - ΔCTcontused). 
! 
X
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Bioinformatics were preformed using validated gene targets of selected miRNAs 
from the miRWALK online database (Dweep et al., 2011).  Gene cross-referencing was 
performed using a Visual Basic/Microsoft Excel based bioinformatics macro script 
developed within our laboratory, available upon request.  Results were generated into a 
table listing the miRNAs of interest in separate column headings, and the gene targets 
for each studied miRNA that were regulated by 2 or more of the 6 total investigated 
miRNAs were listed under the column heading corresponding to the regulating miRNAs.  
This list was indexed in alphabetical order by gene, with each gene having a unique table 
row, to cross-list all miRNAs targeting that specific gene.  Each cross-referenced list was 
grouped according to common gene targets, with 2 groups being formed: one for miR1 
and miR124, and a second for miR21 and miR146a.  Each grouped list contained only 
those genes common between both constituent miRNAs, and analyzed for functional 
annotation in DAVID Bioinformatics Resources for functional annotation (Dennis et al., 
2003; Huang da et al., 2009). 
 
2.4 Results 
2.4.1 Identification and quantification of significant changes in miRNA expression  
Initially, miRNA expression was quantitatively assessed in total RNA samples from 
animals harvested 4 and 14 days post SCI (5 contused and 5 sham animals each) using a 
miRNA microarray approach (for details, see Section 2.3.5).  Microarray data were 
subjected to exploratory analyses using a 2-way ANOVA (SCI lesion condition x Time) 
with a Benjamini and Hochberg correction for multiple comparisons (False-discovery 
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rate (FDR)-set at a=0.1, fold-change cutoff, 1.8-fold).  We identified 31 statistically 
significant, dysregulated small RNAs (30 miRNAs and 1 small nuclear RNA, SNORD2) 
that exhibited a significant main effect of SCI.  Most miRNAs were down-regulated and 
despite an overall significant main effect of SCI, exhibited a greater decline at 14 days 
rather than at 4 days (e.g., miR124, miR129-2, miR129-1, Figure 2a).  Conversely, the 
relatively few small RNAs that exhibited a statistically significant increase, tended to 
exhibit a greater increase at 4 days post SCI, compared to 14 days (e.g., miR21, 
SNORD2, Figure 2a).  Despite this, hierarchical cluster analysis of the FDR-controlled, 
statistically significant small RNAs indicated that the 4 and 14-day sham controls 
clustered together within one linkage group, and SCI groups clustered together within a 
second linkage group, reaffirming the ANOVA-identified dominant main effect of SCI 
(Figure 2b, c).  As a result, we collapsed the dimension of time and conducted t-tests 
with Benjamini and Hochberg FDR corrections to initially screen for SCI-regulated 
miRNAs (FDR-adjusted α = 0.05, fold-change cutoff, 1.5-fold).  Results indicated a 
group of 36 small non-coding RNAs that were significantly dysregulated following SCI, 
4 up-regulated and 32 down-regulated. 
Additional studies were confined to the 3 miRNAs (miR223, miR21, miR146a) 
exhibiting the greatest increase and 4 miRNAs (miR124, miR1, miR129-2, miR129-1) 
exhibiting the greatest decrease in expression, respectively.  The expression of selected 
miRNAs post-SCI was further examined by qRT-PCR in order to validate microarray 
results, and expand the study to investigate expression changes present at 24 hrs and in 
regions 1 cm rostral and caudal to the injury site (Figure 3).  Multivariate ANOVA of 
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Figure 2.  Analysis of microarray expression data indicates that SCI results in significant dysregulation of 
small RNAs.  a, Bar graph depicting expression of significantly dysregulated miRNAs and other small 
RNAs (e.g. SNORD2) over time and experimental condition.  The y-axis depicts fold change in intensity 
relative to a complex RNA target (a composite of equal RNA concentrations from all sham-lesioned 
animals at 4 and 14 days post-surgical manipulation). Data are expressed as ±SEM, with asterisks 
indicating statistical significance compared with sham controls (*p < 0.05, **p < 0.01).  b,c, A hierarchical 
cluster dendogram of microarray data depicting principal component analysis (b), along with Euclidean 
distance and linkage (c), denotes that while both sham groups are similar to each other and both contused 
groups are likewise similar to each other, in terms of miRNA expression profiles, sham groups exhibited a 
low association with contused groups. 
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Figure 3.  Bar graphs depicting qRT-PCR analysis of miRNA expression at the lesion site (a) and in 
regions rostral and caudal to the lesion (b) following SCI.  a,b, The x-axis denotes miRNA of interest, and 
the y-axis denotes the fold expression change using the formula 2-ΔΔCT, where ΔΔCT represents the mean 
difference of sham and contused ΔCT values.  Animals received either a T12-T13 spinal contusion or 
laminectomy only (sham), and sacrificed at 24 hrs, 4 days, or 14 days post-surgery.  The harvested cords 
were analyzed for miRNA expression within the injury site (a) and in spinal cord sections 1 cm rostral and 
caudal to the injury site (b). Data are expressed as a magnitude of change (a value of zero equates to no 
change between surgery conditions, positive values equate to increases in expression following SCI, and 
negative values vice versa), with asterisks indicating significance (f-LSD) compared with sham controls; p 
values are as indicated in the text. 
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qRT-PCR data indicated a significant interaction effect between surgery condition and 
time (Pillai’s Trace Statistic, F(10,26) = 2.722; p<0.02).  In addition, post hoc univariate 
ANOVA indicated a significant main effect of surgery condition on miR124 and miR1 
expression (F(1,16) = 6.774, p<0.02 and F(1,16) = 7.319, p<0.02, respectively), and a 
significant interaction effect between time and surgery condition on miR21 and miR146a 
expression (F(2,16) = 8.918, p<0.01 and F(2,16) = 3.964, p<0.05).  Furthermore, post hoc 
least significant difference t-tests indicated that both miR124 and miR1 exhibited 
significant down-regulation at 4 days post-SCI (pmiR124<0.005 and pmiR1<0.05), as well as 
at 14 days (pmiR124<0.01 and pmiR1<0.05; Figure 3a).  In contrast, miR21 was 
significantly up-regulated at 4 days and down-regulated at 14 days (p<0.001 and p<0.01, 
respectively).  Interestingly, close examination of expression data for miR146a reveals 
that, although the interaction effect between time and condition results in a significant 
trend of increasing miR146a expression in contused subjects over the time course of 24 
hrs to 14 days post-SCI (Student’s 2-tailed t-test, p<0.05), none of the individual time 
points exhibited a significant change by surgery condition.  The primary contributors to 
the significance of this trend are decreased miR146a expression at 24 hrs and increased 
expression at 14 days, relative to sham controls (Student’s 2-tailed t-test, p = 0.064 and p 
= 0.114, respectively).   
Conversely, not only did miR223 lack multivariate significance, but post-hoc 
univariate ANOVA also failed to indicate a significant main effect of spinal cord injury 
on miR223 expression (F(2,16) = 3.964, p<0.09), although these data do suggest a trend 
towards significance.  Preliminary microarray and qRT-PCR data (unpublished data) 
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indicated that miR223 was only significantly up-regulated at 4 days, but this could not 
be validated.  Therefore, although miR223 showed significance at 14 days (Student’s 2-
tailed t-test, p<0.02; Figure 3a) in the qRT-PCR assay for this study, its inconsistence 
with previous observations, along with its high variability in expression between both 
individual specimens and separate assays, led us to exclude it from further analysis. 
Mature miR129-2 and miR129-1 transcripts share nearly identical sequence homology (a 
one nucleotide difference; they are 3’ products formerly denoted as miR129-3p and 
miR129*, respectively) and exhibited similar expression patterns, so they were analyzed 
together as a separate group.  The multivariate ANOVA revealed an overall significant 
main effect of spinal cord lesion (Pillai’s Trace Statistic, F(2,22) = 5.374; p<0.02).  
Furthermore, post hoc univariate ANOVA also indicated a significant main effect of 
condition for both miR129-2 and miR129-1 (F(1,23) = 8.721, p<0.01 and F(1,23) = 9.097, 
p<0.01, respectively).  Student’s 2-tailed t-tests of expression changes at individual time 
points confirmed significant down-regulation at 4 days for both miR129-2 and miR129-1 
(p<0.05, for both), but only for miR129-1 at 14 days (p<0.02; Figure 3a).  In addition, 
miR129-2 and miR129-1 both exhibited a significant decrease in expression in sections 
rostral to the injury site at 14 days post-SCI (p<0.05, for both; Figure 3b). 
 
2.4.2 Impact of injury severity on miRNA expression 
 To explore the possibility that initial injury severity is predictive of dysregulated 
miRNA expression, locomotor function was routinely observed following surgery and 
scored using the Basso, Beattie, and Bresnahan (BBB) scale (Basso et al, 1995).  
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Regression analysis of explained variance revealed that 74.6% of the variation in the 
expression of miR129-2 (-ΔΔCT) on Days 4 and 14 was explained by the variation in 
initial BBB scores (logarithmic R2=0.746, F(1,8)=23.437, p<0.001; Figure 4a), while 
69.7% of the variation in the expression of miR146a on Day 14 was explained by 
variation in BBB score at 24 hrs (R2=0.697, F(1,5)=8.585, p<0.05; Figure 4b). Although 
no other miRNAs were statistically related to injury severity, two instances of significant 
correlation between miRNAs were found.  There was a statistically significant 
correlation between the expression of miR129-1 and miR129-2 (Pearson’s r = 0.851, 
p<0.05; Figure 4c), and between miR124 and miR21 (Pearson’s r = 0.897, p<0.05; 
Figure 4d), suggesting that these pairs of miRNAs may be co-regulated.    
 
2.4.3 MiRNA localization patterns and cellular identity following SCI 
Using in situ hybridization assays, we observed that miRNAs sensitive to spinal cord 
injury exhibit divergent temporal and spatial patterns.  Initially, the possibility of false 
positives resulting from procedural abnormalities and high background was assessed 
using a scrambled miRNA (nonsense control), whose hybridization was acceptably 
minimal (i.e., at near background levels; Figure 5b, see insert), even within the lesion 
site.  MiR124 expression at 4 days post-SCI in sham controls was largely confined to 
laminae VI-IX, with minimal expression in the dorsal horn (Figure 5a).  At 14 days post-
SCI, miR124 exhibited low expression within the injury site compared to the sham 
control, but was present in intact central grey matter tracts (Figure 5b, c), indicating a  
population of surviving neurons.  Similarly, miR1 was down-regulated in grey matter at 
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Figure 4. Regression analyses to assess the relationship between miRNA expression and initial injury 
severity.  a,b, The x-axis represents the Basso, Beattie, and Bresnahan (BBB) score for baseline locomotor 
function, 24 hours following spinal cord contusion, and the y-axis depicts the difference in cycle threshold 
change (-ΔΔCT; a DDCT value of 1 indicates a 2-fold change in miRNA expression) between contused 
subjects and sham controls.  Best-fit curves and correlation constants were generated using least squares 
regression analysis.  Regression analysis indicates that 74.5% of the variation in the expression of 
miR129-2 (-ΔΔCT) on Days 4 and 14 is explained by the variation in BBB scores, 24 hours following SCI 
(Logarithmic regression R2=0.746, F(1,8)=23.437, p<0.001; a), and 69.7% of the variation in miR146a on 
Day 4 is explained by variation in the BBB scores, 24 hours following SCI (Linear Regression R2=0.697, 
F(1,4)=9.189, p<0.05; b).  c,d, Correlation analyses also confirmed that miRNAs correlate with each other.  
The x-axis and y-axis each denote –ΔΔCT values for different miRNAs.  Pearson’s correlations indicated 
significant correlations between miR129-1 and miR129-2 (Pearson’s r = 0.851, p<0.05; c), and between 
miR124 and miR21 (Pearson’s r = 0.897, p<0.05; d), suggesting that these pairs of miRNAs may be co-
regulated.  Data are represented as the difference in cycle threshold change of each contused subject 
relative to the mean cycle threshold change of sham controls (-ΔΔCT= ΔCT sham - ΔCTcontused). 
! 
X
  
 
39 
 
 
Figure 5.  In situ hybridization analyses for miR124 and miR1 expression following SCI.  a-e, Red 
fluorescence is indicative of miRNA expression, whereas blue fluorescence represents DAPI nuclear 
staining.  Each micrograph is a composite of 25 separate micrographs per fluorescence channel at 20X 
magnification tiled together.  a, Coronal localization of miR124 in sham controls was largely confined to 
laminae VI-IX of the grey matter, with minimal expression observed in the white matter.  Dashed lines 
demarcate the grey matter boundaries.  b, MiR124 exhibits reduced expression at the injury site of 
contused animals at 14 days post-SCI and localizes to grey matter tracts (hybridization pattern was similar 
at 4 days; data not shown). The scrambled miRNA control exhibited virtually undetectable levels of 
hybridization confirming the validity of the observed hybridization, as well as with other miRNA-targeted 
probes.  Dashed yellow lines illustrate the orientation of the tiled micrographs stitched together to form 
one image.   c, High magnification photomicrograph of sham control in (b) shows that miR124 localizes 
primarily to soma of large neuronal cells (indicated by arrows) in the grey matter of control animals.  This 
neuronal hybridization is lost following SCI.  d, MiR1 expression is reduced at the injury site of contused 
animals at both 4 and 14 days post-SCI and localizes to grey matter tracts.  Expression in contused 
specimen was confined to peri-lesion tissue.  e, High magnification photomicrograph of sham control in 
(d) indicates that miR1 expression is bound primarily to the neuropil with minimal expression in large 
neuronal cells.  Arrows indicate cytoplasmic presence of miR1 in presumptive glial cells and asterisks 
denote miR1-rich areas of the neuropil.  Dashed lines demarcate  large, presumptive neuronal cells that do 
not express miR1.  Abbreviations, central canal (CC), dorsal horn (DH), grey matter (GM), ventral horn 
(VH), and white matter (WH).  Scale bars, 500 µm (a, b, d) and 50 µm (c, e). 
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the injury site of both 4 and 14 day specimens relative to sham controls, with expression 
being confined to peri-lesion tissue (Figure 5d).  MiR1 expression localized primarily to 
the neuropil, and to the soma of small cells, while hybridization was absent in large 
neuronal-like cells (Figure 5e).  Consistent with the qRT-PCR results, miR21 expression 
was decreased relative to controls at 14 days, but dramatically increased at 4 days 
(Figure 6a, b).  Coincidentally, our laboratory previously reported that miR21 acts as an 
anti-apoptotic factor in fetal mouse cerebral cortex-derived progenitors (Sathyan et al., 
2007), so the significant indication of heavy miR21 up-regulation at 4 days was of 
particular interest.  In order to determine if this marked increase was due to a neural pro-
survival response or from the presence of neural progenitors, immunofluorescence 
analysis for nestin (a neural progenitor factor) was performed immediately upon 
completion of the in situ hybridization protocol.  Interestingly, expression of both nestin 
and miR21 increased substantially in central grey matter bands near the lesion site 
relative to sham controls, and exhibited a high degree of co-localization (Figure 6a).  
Coronal sections of the lesion site indicated that the increased miR21 expression 
observed in longitudinal sections extends throughout the grey matter, including both the 
dorsal and ventral horns, with low expression observed in the surrounding white matter  
(Figure 6b).  Furthermore, expression of both miR21 and nestin was largely absent in 
peri-lesion tissue, suggesting that the sharp increase in miR21 expression, validated with 
qRT-PCR, was primarily bound to lesion-associated, immature neural cells (Figure 6a).   
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Figure 6. In situ hybridization analyses for miR21 expression at 4 and 14 days following SCI. a, 
Substantially increased expression of miR21 was observed within the grey matter at 4 days in contused 
animals and co-localized with nestin, indicated by yellow fluorescence (red = miR21; green = nestin).  
High magnification photomicrograph excerpts from the lesion site at 4 days show that nestin and miR21 
co-localize to cells with small nuclei, and nestin appears globular as opposed to the fibrous morphology 
typically associated with astrocytes.  Furthermore, miR21 is only observed within grey matter at the lesion 
site, with low peri-lesion expression.  In contrast, decreased miR21 expression relative to sham animals 
was observed within grey matter tracts at the injury site 14 days post-SCI.  b, MiR21 localizes throughout 
the grey matter tissue of coronal sections, including both the dorsal and ventral horns, with minimal 
expression in white matter.  The coronal image of the lesion site is an overlaid composite of 4 coronal 
images of the same contused section, each containing 25 micrographs at 20X magnification stitched 
together per fluorescence channel, for an overall total of 200 micrographs stitched together to form one 
image (25 images per channel x 2 channels x 4 stitched coronal micrographs = 200 images).  
Abbreviations, central canal (CC), dorsal horn (DH), grey matter (GM), ventral horn (VH), and white 
matter (WH).  Scale bars, 500 µm (a, b) and 50 µm (high magnification excerpts a, b). 
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 The hybridization patterns for miR129-2 and miR129-1 at 4 days post-SCI were 
similar, comprised of high expression in cells near the lesion but low expression in peri-
lesion tissue, particularly in white matter, relative to sham controls (Figure 7a, 6b).  
Specifically, in sham-lesioned control animals, expression of miR129-1 was observed 
within the cytoplasm of large neuronal-like cells (Figure 7c).  In contrast, at 14 days 
post-lesion, miR129-1 expression was virtually undetectable within the lesion site, and 
was notably present only in peri-lesion grey matter tracts  (Figure 7d).  In addition, 
miR129-1 and miR129-2 were both negatively regulated in sections rostral to the injury 
site at 14 days, with expression primarily limited to grey matter tracts, and low 
expression throughout the white matter. 
Subsequently, immunofluorescence analyses of biomarkers present at 14 days 
post-SCI was performed to correlate cellular identity after SCI with miRNA expression 
patterns.  Following SCI, nestin expression was observed at the lesion site throughout 
the gray matter, including both the dorsal and ventral horns, which typically indicates 
either the presence of neural progenitor cells involved in the adaptive formation of new 
neurons, or reactive astrocytes contributing to glial scar formation (Gilyarov, 2008; 
Figure 8a-e).  However, in contrast to the gray matter localization of nestin, glial 
fibrillary acidic protein (GFAP), an intermediate filament specific within the CNS to 
astrocytes and other glial cells, was primarily observed in the white matter following 
SCI, though nominal expression was observed in grey matter as well (Figure 8f-h).  
Although there was notable presence of reactive astrocytes (nestin+/GFAP+), the lesion 
site also contained large networks of nestin+/GFAP- cells containing neuronal
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Figure 7. In situ hybridization for miR129-2 and 129-1 at statistically significant time points following 
SCI as determined from qRT-PCR.  a-d, Red fluorescence is indicative of miRNA expression, whereas 
blue represents nuclear (DAPI) fluorescence.  a, Decreased expression of miR129-2 was observed at 4 
days in peri-lesion tissue of contused animals, but expression was present within the lesion site itself.  b, 
Similarly, miR129-1 followed the same localization pattern at 4 days with expression being bound to 
lesion-associated cells only.  c, High magnification micrograph of sham control at 4 days post-SCI shows 
both cytoplasmic and nuclear labeling of miR129-1 in the neuropil and large neuronal cells, indicated by 
asterisks and arrows, respectively.  d, Conversely, expression at 14 days post-SCI was low within the 
lesion itself and localized predominately with peri-lesion grey matter at the rostral and caudal sectional 
extremes, with decreased expression also observed in tissue 1cm rostral to the lesion site. Scale bars, 500 
µm (a, b, d) and 50 µm (c). 
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Figure 8. Expression of biomarkers for neural differentiation is consistent with the emergence of neuronal 
immaturity in addition to reactive astrocytes.  a-e, Nestin expression is increased in contused specimens 
both 4 and 14 days after SCI.  a, Increased nestin expression was observed throughout the grey matter, and 
in both the dorsal and ventral horns, in coronal sections of contused animals 4 days following injury.  b-d, 
High magnification micrographs show nestin fiber tracts associated with small glial cells in the white 
matter/remnants of the dorsal horn (b), nestin positive cells along the interface between the ventral horn 
and white matter (c), and a large, nestin positive neuronal cell projecting into the white matter from the 
ventral horn (d).  Arrows label nestin-labeled processes of the neuron, and an asterisk denotes the large 
nucleus; note the triangular shaped cell body and long axonal process.  e, At 14 days post-surgery, 
contused specimens illustrated a higher level of nestin expression than that observed at 4 days, relative to 
sham controls.  f-i, In addition to nestin, contused specimens also exhibited an increase in GFAP (f), but 
expression was largely confined to white matter (g, h) and GFAP and nestin did not co-localize 
exclusively.  i, Large numbers of nestin+/GFAP- cells with long processes were observed within the lesion 
site, indicative of neuronal immaturity rather than reactive astrocytosis.  Abbreviations, central canal (CC), 
dorsal horn (DH), grey matter (GM), ventral horn (VH), and white matter (WH).  Scale bars, 500 µm (a, c, 
f-h), 200 µm (e, i) and 50 µm (b, d). 
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morphologies such as long axonal-like processes and large nuclei (Figure 8i), whereas 
sham controls exhibited minimal nestin expression (Figure 8e).  In addition, REST, a 
transcription factor present in neural progenitor cells and indirectly inhibited through a 
negative feedback loop by miR124 to induce neuronal fate (Visvanathan et al., 2007), 
was up-regulated in and adjacent to the lesion site, but not in sham controls (Figure 9a-
d).  Furthermore, expression of neurofilament was localized to fibers running proximal 
and parallel to nestin-positive processes, but did not display co-localization (Figure 10a), 
indicative that the nestin-positive cells are not mature neurons (Figlewicz et al., 1988; 
Lagace et al., 2007).  To address the possibility that the nestin+/GFAP- regions are 
active sites for adult neurogenesis following SCI, tissue was immunostained for nestin 
and the transcription factor SOX2, a positive regulator of nestin during neurogenesis that 
is expressed in stem and progenitor cells (Jin et al., 2009).  Interestingly, at 4 days, 
SOX2 expression was observed throughout the grey matter, including both the ventral 
and dorsal horns (Figure 10b), specifically in two groups of cells within the lesion site: 
within clusters of small, immature cells that were also nestin-positive (indicating 
activation of stem cell niches within the lesion site; Figure 10d), and within nuclei of 
large neuronal cells (Figure 10c, e).  The expression of Sox2 in the latter cell population, 
while not co-localized with nestin (Figure 10f), was nevertheless consistent with the 
disappearance of miR124 (Figure 5b) and the appearance of REST (Figure 9a-d), and 
supports a hypothesis that neurons within the lesion site transiently revert to a more 
immature phenotype.  In contrast, substantially lower levels of SOX2 were observed
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Figure 9.  Expression of REST is increased following SCI.  a, REST expression at 14 days was increased 
in cells within and adjacent to the lesion site, but not in sham controls.  b, Boxed in sections from (a) are 
shown in higher magnification in adjacent panels (20X and 40X, respectively).  c, Expression of REST at 
4 days increased within both white and grey matter of coronal sections, including the dorsal and ventral 
horns.  d, High magnification micrograph shows cytoplasmic REST expression in large neuronal cells 
(indicated by arrows) of a contused specimen 4 days post-SCI.  Abbreviations, central canal (CC), dorsal 
horn (DH), grey matter (GM), ventral horn (VH), and white matter (WH).  Scale bars, 500 µm (c), 200 µm 
(a) and 50 µm (b, d). 
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Figure 10. Expression of SOX2 is increased following SCI.  a, Nestin and neurofilament fiber tracts run 
parallel to one another, but do not co-localize, indicating that nestin+ cells are not mature neurons.  The 
globular appearance of red immunofluorescence is indicative of neurofilament depolymerization within 
injured neurons at the lesion site.  Arrows point to nestin immunoreactive fibers within the lesion site 
perforating through a region of grey matter containing damaged neurons labeled with globular 
neurofilament-like immunofluorescence.  b-e, Localization of SOX2 at 4 days post-SCI.  SOX2 was 
observed throughout the grey matter in coronal sections, including both the dorsal and ventral horns (b), 
and high magnification micrographs illustrate both cytoplasmic and nuclear labeling within large neuronal 
cells, indicated by arrows and asterisks, respectively (c).  SOX2 (red) co-localizes to small clusters of 
nestin positive cells (green) within the lesion site (d), indicating emergence of neural progenitor cells 
following SCI.  SOX2 expression (red, arrows) is also observed in nestin-negative neuronal cells in the 
peri-lesion region (e).  f, At 14 days post-SCI, low levels of SOX2 expression are observed following 
injury, and SOX2 does not co-localize with nestin, suggesting that these nestin-positive cells are further 
differentiated towards their neuronal lineage.  Abbreviations, central canal (CC), dorsal horn (DH), grey 
matter (GM), ventral horn (VH), and white matter (WH).  Scale bars: 500 µm (b) and 50 µm (a, c-f). 
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at 14 days, along with increased nestin expression, and co-localization with nestin was 
negligible (Figure 10g). 
 
2.4.4 Bioinformatics analyses of miRNA targets  
To determine the functional significance of miRNA expression changes, validated gene 
targets of miRNAs were obtained from miRWALK (Dweep et al., 2011) and cross-
referenced to determine gene targets common between multiple miRNAs.  These lists 
were then grouped into two categories, those that were common targets of miR1 and 
miR124, and a second group containing common targets of miR21 and miR146a.  The 
resulting gene lists were then analyzed using the DAVID Bioinformatics Resources for 
functional annotation (Dennis et al., 2003; Huang da et al., 2009; Table 1).   
Quantitative RT-PCR data indicated that both miR1 and miR124 were down-
regulated at 4 and 14 days, and initial bioinformatics showed that they target similar 
types of genes, so they were grouped together for functional analysis.  Functional 
annotation revealed that both miRNAs are inhibitors gene networks that promote 
transcription and translation (for significant Gene Ontologies, see Table 1), and their 
down-regulation results in an increase in protein synthesis that contributes to the 
initiation of cell cycle, induction of apoptosis, and response to inflammation.  
Interestingly, inhibition of these miRNAs also promotes cell motility, which is indicative 
of the emergence of immature cells and, in conjunction with cell cycle initiation, 
reaffirms the immunofluorescence observations that neurons at the injury site appear to 
be shifting to a pre-neuronal state.  
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Table 1. Statistical annotation of miRNA function.  Gene targets of SCI-sensitive miRNAs, were 
identified using miRWALK (Dweep et al., 2011).  This analysis was limited to miRNA gene targets that 
were identified from the published literature and cross-referenced for gene targets shared by two or more 
SCI-sensitive miRNAs.  The cross-referenced lists were grouped according to similarity, and functional 
annotation by Gene Ontology Term (Ashburner et al., 2000) was performed in two groups, one for miR1 
and miR124, and another for miR21 and miR146a common targets (Dennis et al., 2003; Huang da et al., 
2009).  Enriched Gene Ontologies were retained when the Benjamini corrected Fisher Exact t-test p-value 
was less than 0.05. 
Gene Ontology ID ~ functional term Gene 
Count 
Benjamini  
p-value 
    
miR-1 and miR-124 common targets   
GO:0006357~regulation of transcription from RNA polymerase II promoter 17 1.72E-02 
GO:0006928~cell motion 12 4.70E-02 
GO:0010608~posttranscriptional regulation of gene expression 8 4.66E-02 
GO:0022402~cell cycle process 13 4.67E-02 
GO:0032268~regulation of cellular protein metabolic process 17 6.03E-04 
GO:0042981~regulation of apoptosis 17 3.67E-02 
GO:0043065~positive regulation of apoptosis 12 3.61E-02 
GO:0045449~regulation of transcription 35 4.29E-02 
GO:0048545~response to steroid hormone stimulus 9 1.61E-02 
h_tnfr1Pathway:TNFR1 Signaling Pathway 7 8.39E-04 
    
miR-21 and miR-146a common targets   
GO:0008284~positive regulation of cell proliferation 6 6.94E-03 
GO:0008285~negative regulation of cell proliferation 6 4.28E-03 
GO:0009628~response to abiotic stimulus (radiation, UV) 8 8.54E-05 
GO:0032268~regulation of cellular protein metabolic process 7 1.69E-03 
GO:0033554~cellular response to stress 6 2.26E-02 
GO:0042127~regulation of cell proliferation 11 2.69E-05 
GO:0042981~regulation of apoptosis 10 1.11E-04 
GO:0043065~positive regulation of apoptosis 9 2.71E-05 
GO:0043066~negative regulation of apoptosis 6 4.20E-03 
GO:0044451~nucleoplasm part 7 1.53E-02 
GO:0045449~regulation of transcription 12 1.29E-02 
hsa04010:MAPK signaling pathway 7 3.81E-03 
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MiR21 and miR146a were both transiently induced following SCI and also had 
similar validated gene target profiles, so they were analyzed together as a second 
functional group.  Functional annotation illustrates that miR21 and miR146a act 
primarily to inhibit cell proliferation and apoptosis through the regulation of 
transcription and translation.  In addition, due to their association within the same 
annotation cluster, it is possible that the primary method by which these two miRNAs 
regulate cell proliferation is through the inhibition of gene ontology groups including the 
MAPK signaling and nucleoplasm production pathways (Table 1).  
Finally, analysis was not performed for miR129-2 and miR129-1 because 
validated targets have not been published, and the analysis of predicted targets did not 
produce statistically significant Gene Ontologies.  Further study may be needed to 
determine valid gene targets of the miR129 family, or to functionally analyze validated 
targets as they become available in published literature. 
 
2.5 Discussion 
Spinal cord injury dramatically alters the cellular landscape of impacted tissue through 
the activation of inflammatory pathways, which ultimately cause further insult by 
contributing to the pathogenesis of secondary SCI, instead of protective mediation.  The 
resulting loss of cellular plasticity, especially in the presence of uncontrollable 
nociceptive stimuli, impairs therapeutic efforts to improve functional recovery (Grau et 
al., 2006; Hook et al., 2009). Because microRNAs are capable of regulating hundreds of 
genes simultaneously, either post-transcriptionally or through promoter interaction (Li et 
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al., 2006; Breving and Esquela-Kerscher, 2010), it is likely that they play a major role in 
the induction of these maladaptive processes following SCI, and could therefore become 
attractive candidates for drug targets in therapeutic intervention for spinal cord injury.  
In the current study we investigated the regulation of microRNAs after SCI.  
Specifically, we identified 7 miRNAs using microarray analysis that were significantly 
altered within 4 to 14 days after SCI (223, 21, and 146a positively and 1, 124, 129-2, and 
129-1 negatively).  Additionally, one other non-coding small RNA, SNORD2, an ATP-
dependent helicase important for ribosome-associated translation initiation (Sudo et al., 
1995; Hernandez and Vazquez-Pianzola, 2005), was also significantly induced within 
the lesion site. These data collectively suggest that cellular adaptation to injury involves 
simultaneous inhibition and initiation of translation resulting in a shift in protein 
expression profiles in the injury site.  
Using both qRT-PCR and in situ hybridization analyses, we were able to validate 
the differential SCI-related expression of all the above miRNAs except for miR223.  In 
contrast to recent reports by Nakanishi et al. (2010), who found that miR223 expression 
was significantly induced early following injury (6-12 hours, post SCI), we observed 
that at best, miR223 was induced as a later component (14 days post-SCI) of injury.  
While we do not as yet understand the source of these temporal variations in miR223 
expression, miR223 has recently been implicated in myeloid cell differentiation and may 
play a role in inflammation (Johnnidis et al., 2008; Pedersen and David, 2008; Tsitsiou 
and Lindsay, 2009).  Consequently, miR223 expression could represent a signature for 
infiltration of immune cells into the injury site.   
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Additionally, we found that miR21 was initially induced and then suppressed at 
the lesion site.  Suppression of miR21 has been shown to cause apoptosis in both cortical 
progenitor cells and gliomas (Corsten et al., 2007; Sathyan et al., 2007; Krichevsky and 
Gabriely, 2009), so the observed up-regulation of miR21 at 4 days, in conjunction with 
the simultaneous re-expression of nestin, would suggest a protective role in promoting 
cell survival and neural progenitor cell integration at the lesion site.  While miR21 was 
transiently increased following SCI, miR146a exhibited a more prolonged increase up to 
14 days post SCI.  Accumulating evidence indicates that miR146a acts not only as an 
anti-inflammatory mediator because it inhibits the translation of a number of cytokines 
and chemokines, including IL-6, IL-8, IL-1β and TNF-α (Taganov et al., 2006; Li et al., 
2010a), but also as a pro-growth miRNA, as evidenced by its promotion of cell 
proliferation in hepatocellular carcinoma (Xu et al., 2008).  Indeed, a functional analysis 
of validated (published) gene targets of SCI-sensitive miRNAs (miRWALK) indicates 
that both miR21 and miR146a inhibit expression of genes that repress cell proliferation 
and promote apoptosis.  It is therefore possible that miR146a compensates for the 
decline in miR21, and in doing so, supports cell and tissue growth following SCI, in 
addition to reducing overall inflammation at the injury site.  
We also observed that miR129-2 and miR129-1 were significantly suppressed at 
4 days post-SCI, and that this suppression spread rostrally beyond the lesion site at 14 
days.  Recent evidence shows that the miR129 family inhibits the G1/S phase-specific 
regulator CDK6, and consequently, miR129 suppression allows post-mitotic, G1 phase-
arrested cells to proliferate (Wu et al., 2010).  Such aberrant cell cycle entry could 
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ultimately lead to significant neuronal death (Di Giovanni et al., 2003; Herrup and Yang, 
2007).  This maladaptive proliferation caused by miR129 down-regulation is 
contradictory to the pro-growth proliferation induced by increased levels of miR21 and 
miR146a, which collectively illustrates that the balance between miRNAs like miR21, 
miR146a, and miR129 may well play a critical role in neuronal survival following SCI.   
Interestingly, miR146a and miR129-2 exhibited divergent expression patterns 
(miR146a was up-regulated and miR129-2 was suppressed) following SCI, when 
compared to sham control cohorts.  However, within the cohort of SCI animals 
themselves, the initial severity of the lesion was inversely related to later expression of 
both miRNAs. A less severe injury, as measured by the BBB score on day 1 post-SCI, 
was associated with increased expression of both miR146a and 129-2 at 4 and up to 14 
days later.  Moreover, the initial severity of the injury could explain a large and 
significant proportion of the variability in miRNA expression (63% and 75% for 
miR146a and miR129-2 respectively), suggesting that these miRNAs in turn may serve 
as effective therapeutic targets or proxy measures for the severity of an injury.  
Importantly, expression of none of the other SCI-regulated miRNAs were related to the 
severity of the injury, suggesting that most other miRNAs respond to injury in a more or 
less “all or none” manner.  
We also observed that following SCI, both miR1 and miR124, best known for 
their critical role in maintaining the differentiation states of cells and tissues, exhibited a 
persistent and significant decline.  MicroRNA-124, thought to be a neuronal-specific 
miRNA, drives ectoderm differentiation towards a neuronal lineage through a negative 
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feedback loop that inhibits REST-mediated repression of neuronal genes, while 
simultaneously down-regulating non-neuronal genes (Visvanathan et al., 2007). In 
contrast, miR1 is best known for its capacity to drive mesoderm differentiation into 
either skeletal or cardiac muscle fates by silencing non-muscle genes (Chen et al., 2006; 
Ivey et al., 2008; Williams et al., 2009), although this miRNA is also expressed in neural 
tissue like the brain and spinal cord (Mishima et al., 2007), as well as in the retina, where 
its expression is altered in several models of retinal neurodegeneration (Loscher et al., 
2008).  The steep decrease in miR124 expression in the lesion site of contused animals, 
specifically within the grey matter bands and within the large presumptive motor-
neuronal cells, could be partly attributed to the high degree of neuronal death resulting 
from the primary injury (Nakanishi et al., 2010).  However, SOX2 and REST were both 
up-regulated in large motorneurons that had lost miR124 expression in regions proximal 
to the lesion site, suggesting that cellular de-differentiation, aside from death, underlies 
the observed decrease in miR124.  Thus, a likely synergistic effect of the concurrent 
suppression of both miR1 and miR124 would be the transient emergence of a cellular 
environment highly favorable for plasticity and neural fate reprogramming.  However, 
any early increase in neuronal plasticity at the lesion site, mediated by miR124/miR1 
suppression, may ultimately synergize with the pro-apoptotic, pro-cell cycle effects of 
suppressing miR21/miR129 at 14 days to cause cell cycle failure and induction of 
apoptosis in surviving post-mitotic neurons. 
The lesioned spinal cord exhibits additional evidence for cellular plasticity in the 
form of activated stem cell niches.  While some nestin-positive cells co-localize with 
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GFAP, indicating the presence of reactive astrocytes, other networks of nestin-positive 
cells did not exhibit such co-localization.  Moreover, within the lesion site, we also 
observed clusters of nestin-positive cells that also express SOX2, a stem cell-associated 
transcription factor that controls nestin expression in neural progenitor cells of the CNS 
to promote differentiation (Jin et al., 2009).  The presence of SOX2+/nestin+ and 
nestin+/GFAP-cells within the lesion site, 4-days post-lesion, suggests the specific 
activation of stem cell niches and the emergence of cells that exhibit a neuronal 
progenitor identity.  At 14 days post-lesion, nestin-positive cells within the lesion site no 
longer expressed SOX2 suggesting that these cells had progressed further towards a 
neural identity. 
 
2.6 Conclusions 
Our evidence shows that SCI results in a very specific and limited profile of miRNA 
changes, and that these changes evolve in a coordinated manner over a period of time 
following the injury. Interestingly, most changes are limited to the lesion site with very 
limited miRNA dysregulation observed in regions anterior or caudal to the injury site. 
Over a prolonged period (14 days), only three miRNAs also exhibited spatial 
dysregulation.  MiR129-1 and 129-2 were suppressed in regions anterior to the injury 
site, whereas miR146a was increased caudal to the injury site.  Interestingly, both 
miR129-2 and miR146a also exhibit a strong potential to be proxy markers for the initial 
severity of spinal cord injury.  These data collectively suggest that global changes in 
miRNA-driven control of protein-coding gene networks remain largely confined to the 
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lesion site, with minimal initial adaptations within the surrounding non-injured tissue.  It 
remains to be determined whether other miRNA adaptations appear over time in specific 
afferent or efferent targets of projections from within the lesion site, including cortical, 
thalamic or lower motor-neuron targets. 
A statistical analysis of the gene ontology classifications of published mRNA 
targets associated with the miRNAs aberrantly expressed following SCI yields a 
cohesive picture of miRNA involvement favoring a loss of neuronal identity and the 
emergence of neuronal progenitors within the lesion site.  Such a hypothesis is well 
supported by the induced expression SOX2 and nestin within probable stem cell niches.  
It is additionally supported by the expression of both SOX2 and the suppressor of 
neuronal identity, REST, along with the loss of miR124 within surviving, presumptive 
motorneurons within the lesion site.  In the latter case, this loss of neuronal identity may 
well be a factor in the induction of apoptosis driving secondary SCI, but could also 
represent a target of opportunity for therapeutic intervention in the immediate aftermath 
of SCI.  De-differentiating neurons and activated stem cell niches may be subjected to 
reprogramming, possibly using the complement of miRNAs that are dysregulated 
following SCI itself.  Further functional analyses will be required to explore the 
therapeutic and regenerative potential of manipulating levels of these SCI-sensitive 
miRNAs, in the immediate and prolonged time period following an injury, to minimize 
secondary injury and enhance functional recovery. 
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3. THE ASSOCIATION BETWEEN SCI-SENSITIVE MIRNAS AND PAIN 
SENSITIVITY, AND THEIR REGULATION BY MORPHINE  
 
3.1 Overview 
Increased pain sensitivity is a common sequel to spinal cord injury (SCI).  Moreover, 
drugs like morphine, though critical for pain management, elicit pro-inflammatory 
effects that exacerbate chronic pain symptoms.  Previous reports showed that SCI results 
in the induction and suppression of several microRNAs (miRNAs), both at the site of 
injury, as well as in segments of the spinal cord distal to the injury site. We hypothesized 
that morphine would modulate the expression of these miRNAs, and that expression of 
these SCI-sensitive miRNAs may predict adaptation of distal nociceptive circuitry 
following SCI.  Our data indicated that expression of miR1, miR124, and miR129-2 at 
the injury site predicted the nociceptive response mediated by spinal regions distal to the 
lesion site, suggesting a molecular mechanism for the interaction of SCI with adaptation 
of functionally intact distal sensorimotor circuitry. Moreover, the SCI-induced miRNA, 
miR21 was induced by subsequent morphine administration, representing an alternate, 
and hitherto unidentified, maladaptive response to morphine exposure.  Contrary to 
predictions, mRNA for the pro-inflammatory interleukin-6 receptor (IL6R), an identified 
miR21 target, was also induced following SCI, indicating dissociation between miRNA 
and target gene expression.  Moreover, IL6R mRNA expression was inversely correlated 
with locomotor function suggesting that inflammation is a predictor of decreased spinal 
cord function.  Collectively, our data indicate that miR21 and other SCI-sensitive 
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miRNAs may constitute therapeutic targets, not only for improving functional recovery 
following SCI, but also for attenuating the effects of SCI on pain sensitivity. 
 
3.2 Introduction 
The effects of spinal cord injury (SCI) can be severely debilitating, especially the 
chronic presence of neuropathic pain that affects close to two-thirds of all spinal cord-
injured patients (Siddall and Loeser, 2001; Anderson, 2004).  One of the primary 
treatments for chronic pain following SCI is administration of opiate analgesics such as 
morphine, which are also given during the acute phase of spinal injury for pain 
mitigation (Dworkin et al., 2003; McCarberg, 2004).  However, administration of 
morphine in the acute phase of a spinal contusion injury in rats has been shown to 
significantly attenuate locomotor function and increase expression of chronic pain 
symptoms (Hook et al., 2007; Hook et al., 2009).  The increased chronic pain associated 
with morphine administration has been attributed to the activation of astrocytes and 
microglia by morphine and inhibition of analgesic effects by increased expression of 
pro-inflammatory cytokines TNFα, IL-1β, and IL-6 (Song and Zhao, 2001; Raghavendra 
et al., 2002; Johnston et al., 2004; Cui et al., 2006; Tai et al., 2006).  Accordingly, the 
application of an interleukin-1 receptor antagonist prior to intrathecal morphine prevents 
the maladaptive effects of morphine on neuropathic pain and functional recovery (Hook 
et al., 2011).   
While these results are promising, there is limited knowledge of the remodeling 
of pain neuro-circuitry and the activation of potentially maladaptive gene regulatory 
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networks following morphine treatment in SCI.  MiRNAs are short, 18 to 25 nucleotide-
long non-coding small RNAs that play an important regulatory role in gene expression 
by inhibiting protein translation or targeting mRNA transcripts for degradation (Alvarez-
Garcia and Miska, 2005; Zamore and Haley, 2005).  Individual miRNAs are able to 
coordinate gene networks to affect a specific cellular endpoint by simultaneously 
controlling expression of several hundred mRNAs.  Furthermore, miRNAs have been 
implicated in physiological processes relevant to neuropathic pain, including innate 
immune responses involved in wound inflammation (Williams et al., 2008; Roy and Sen, 
2011) and the regulation of inflammation in response to morphine treatment in human 
monocyte-derived macrophages (Dave and Khalili, 2010).   
MiRNAs are also dysregulated following SCI (Liu et al., 2009; Nakanishi et al., 
2010; Strickland et al., 2011; Yunta et al., 2012).  We previously reported that miR124, 
miR129, and miR1 were significantly down-regulated following spinal cord contusion, 
while both miR21 and miR146a were transiently induced, and changes in miR146a and 
miR129-2 expression significantly explained the variability in injury severity (Strickland 
et al., 2011).  We hypothesized that the temporal expression of miR146a, miR21, and 
other SCI-sensitive miRNAs may be further dysregulated following administration of 
morphine in the acute phase of a spinal contusion injury. Such dysregulation could 
constitute an important role in both inflammation and the progression of neuropathic 
pain during the chronic phase of injury.  Moreover, these miRNAs may contribute 
towards the regulation of the nociceptive circuitry and chronic effects of morphine 
exposure.  To assess these possibilities, the current study investigated the relationship 
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between SCI-sensitive miRNA expression and morphine administration, evaluated at 2 
and 15 days post-SCI to explore the effects of acute morphine treatment in both the acute 
and chronic phases of SCI.  In addition, we also investigated the relationship between 
miRNA expression and the variance in baseline and morphine-attenuated pain sensitivity 
following SCI. 
 
3.3 Experimental Procedures 
3.3.1 Subjects 
All of the experiments were reviewed and approved by the institutional animal care 
committee at Texas A&M University and all NIH guidelines for the care and use of 
animal subjects were followed.  Male Sprague–Dawley rats (Rattus norvegicus) obtained 
from Harlan (Houston, TX) at approximately 90-110 days old (300-350 g) were 
individually housed in Plexiglas bins [45.7 (length) x 23.5 (width) x 20.3 (height) cm] 
with food and water continuously available.  To facilitate access to the food and water, 
extra bedding was added to the bins after surgery and long mouse sipper tubes were used 
so that the rats could reach the water without rearing. Subjects were weighed on the 
same days that they were assessed for locomotor function, and were checked daily for 
signs of autophagia and spasticity.  A subject was classified as having spasticity if the 
limb was in an extended, fixed position and was resistant to movement.  Bladders were 
manually expressed in the morning (8:00-9:30 hrs) and evening (18:00-19:30 hrs) until 
subjects regained bladder control, which was operationally defined as three consecutive 
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days with an empty bladder at the time of expression. The rats were maintained on a 12 
hr light/dark cycle and tested during the last 6 hrs of the light cycle. 
 
3.3.2 Surgery 
Subjects were anesthetized with isoflurane (5%, gas). Once a stable level of anesthesia 
was achieved, the inspired concentration of isoflurane was lowered to 2-3% and an area 
extending approximately 4.5 cm above and below the injury site was shaved and 
disinfected with iodine.  A 7.0 cm incision was made over the spinal cord.  Next, two 
incisions were made on either side of the vertebral column, extending about 3 cm rostral 
and caudal to the T12-T13 segment.  The dorsal spinous processes at T12-T13 were 
removed (laminectomy), and the spinal tissue exposed.  The dura remained intact.  For 
the contusion injury, the vertebral column was fixed within the MASCIS device (Gruner, 
1992; Constantini and Young, 1994) and a moderate injury was produced by allowing 
the 10 g impactor (outfitted with a 2.5 mm tip) to drop 12.5 mm.  Sham controls 
received a laminectomy, but the cord was not contused with the MASCIS device.  
Following surgery, the wound was closed with Michel clips.  T12-T13 level contusion 
models have been routinely used by members of our group to define spinal cord learning 
circuits and molecular mechanisms involved with recovery of function (Ferguson et al., 
2008; Brown et al., 2011; Hook et al., 2011). Lesions at this level result in well-defined 
and replicable sensory-motor deficits, and we therefore chose to utilize contusion at this 
level to also examine changes in miRNA expression. 
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An intrathecal cannula was also inserted into the subarachnoid space 
immediately after the contusion injury. For this procedure, a 15 cm long polyethylene 
(PE-10) cannula, fitted with a 0.23 mm (diameter) stainless steel wire (SWGX-090, 
Small Parts), was threaded 2 cm under the vertebrae immediately caudal to the injury 
site. The cannula tip terminated over the S2-S3 spinal segments, so that morphine was 
delivered to the lumbosacral regions mediating hind-paw pain reactivity. To prevent 
cannula movement, the exposed end of the tubing was secured to the vertebrae rostral to 
the injury using an adhesive (Cyanoacrylate). The wire was then pulled from the tubing 
and the wound was closed using Michel clips.  
To help prevent infection, subjects were treated with 100,000 units/kg Pfizerpen 
(penicillin G potassium) immediately after surgery and again 2 days later.  For the first 
24 hrs after surgery, rats were placed in a recovery room maintained at 26.6 0 C.  To 
compensate for fluid loss, subjects were given 2.5 ml of saline after surgery.  Michel 
clips were removed 14 days after surgery. 
 
3.3.3 Drug administration 
After baseline assessments of locomotor and sensory function, rats were assigned to a 
morphine or vehicle treatment group.  Twenty-four hours or 14 days after injury, the rats 
were given an intrathecal infusion of morphine sulfate (90 µg i.t., Mallinckrodt, 
Hazelwood, MI) dissolved in 2 µL of distilled water.  This dose of morphine was chosen 
based on previous studies that demonstrated that this high dose is required to achieve 
strong anti-nociception and block behavioral reactivity to nociceptive stimulation after 
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SCI, as well as being detrimental to long-term recovery of locomotor function (Hook et 
al., 2009; Hook et al., 2011).  Control subjects were treated with 2 µL of vehicle.  These 
drug injections were followed by a 10 µL injection of saline, to flush the catheter.  
Locomotor ability was assessed with the BBB scale prior to and after drug treatment. 
This behavioral index was used to ensure that injury severity was balanced across groups 
prior to drug treatment. 
 
3.3.4 Assessment of locomotor function 
Locomotor behavior was assessed using the Basso, Beattie and Bresnahan (BBB) scale 
(Basso et al., 1995), in an open enclosure (99 cm diameter, 23 cm deep). This 21-point 
scale is used as an index of hindlimb functioning after a spinal injury. Using this scale, 
no movement of the hindlimbs (ankle, knee or hip) is designated a score of 0, and 
intermediate milestones include slight movement of one joint (1), extensive movement 
of all three joints (7), occasional weight supported stepping in the absence of 
coordination (10), and consistent weight supported stepping with consistent FL-HL 
coordination (14). Higher scores reflect consistent limb coordination and improved fine 
motor skill. Baseline motor function was assessed on the day following injury and prior 
to drug treatment. Because rodents often freeze when first introduced to a new apparatus, 
subjects were acclimated to the observation fields for 5 min per day for 3 days prior to 
surgery.  Each subject was placed in the open field and observed for 4 min. Care was 
taken to ensure that the investigators’ scoring behavior had high intra- and inter-observer 
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reliability (all r’s > 0.89) and that they were blind to the subject’s experimental 
treatment. 
 
3.3.5 Sensory reactivity 
For the assessment of morphine efficacy, nociceptive reactivity was assessed 
immediately before and 30 minutes after intrathecal morphine administration.  Thermal 
reactivity was assessed using radiant heat in the tail-flick test. Subjects were placed in 
the restraining tubes with their tail positioned in a 0.5 cm deep groove, cut into an 
aluminum block, and allowed to acclimate to the apparatus (IITC Inc., Life Science, CA) 
and testing room for 15 min. The testing room was maintained at 26.5˚C. Thermal 
thresholds were then assessed. Thermal reactivity was tested using a halogen light that 
was focused onto the rat's tail. Prior to testing the temperature of the light, focused on 
the tail, was set to elicit a baseline tail-flick response in 3-4 sec (average).  This pre-set 
temperature was maintained across all subjects.  In testing, the latency to flick the tail 
away from the radiant heat source (light) was recorded. If a subject failed to respond, the 
test trial was automatically terminated after 8 s of heat exposure. Two tests occurred at 
2-minute intervals, and the second test’s tail-flick latencies were recorded. To confirm 
that subjects did not respond in the absence of the stimuli, blank trials were also 
performed.  A ‘false alarm’ was recorded if subjects made a motor or vocalization 
response during the blank tests. The blank trials were performed 1 min before or after 
each sensory test (in a counterbalanced fashion).  No false alarms were recorded. 
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3.3.6 Isolation of RNA for qRT-PCR  
Subjects were euthanized (100 mg/kg of pentobarbital, i.p.) 24 hrs after drug treatment.  
A 5 mm segment of spinal cord from the injury site, hearts, and carotid arteries were 
collected, snap frozen in liquid nitrogen, and stored at –80 °C until further analysis.  
Specimens were crushed and RNA was isolated using the TRIzol (Invitrogen; Carlsbad, 
CA) protocol.  Total RNA was then quantified using a NanoDrop 2000 
Spectrophotometer (Thermo Scientific; Wilmington, DE) and stored at -80 °C. 
 
3.3.7 Quantitative RT-PCR  
MiRNA expression data was measured with quantitative reverse transcription (qRT)-
PCR for miRNAs, based on the protocol of the miRCURYTM LNA microRNA Universal 
RT-PCR system (EXIQON; Woburn, MA).  RNA samples were converted to cDNA, 
and qRT-PCR was performed using a 7900HT Fast Real-Time PCR System (Applied 
Biosystems, Foster City, CA).  Forward and reverse primers (EXIQON; Woburn, MA) 
for hsa-miR124, hsa-miR1, hsa-miR21, hsa-miR129-2, and hsa-miR146a were used for 
PCR amplification, and real time data was normalized using U6 RNA.  Similarly, 
messenger RNA (mRNA) expression of IL-6 receptor (IL6R) was measured using qRT-
PCR for mRNAs, based on the protocol for PerfeCTa® SYBR® Green SuperMix with 
ROX™ (Quanta Biosciences; Gaithersburg, MD).  RNA samples were converted to 
cDNA using qScript™ cDNA SuperMix (Quanta Biosciences; Gaithersburg, MD), and 
qRT-PCR was performed using a 7900HT Fast Real-Time PCR System (Applied 
Biosystems, Foster City, CA).  Forward and reverse primers (Integrated DNA 
  
 
66 
Technologies; Coralville, IA) for IL-6R were used for PCR amplification, and real time 
data was normalized using glyceraldehyde 3-phosphate dehydrogenase (GAPDH).  
Relative miRNA and mRNA expression was determined by calculating the mean 
difference between cycle threshold of either the miRNA from the U6 small nuclear RNA 
(U6SNB) normalized control, or the IL6R mRNA from the GAPDH normalized control 
for each sample [Δ cycle threshold (ΔCT)] within each sample group (samples with 
same miRNA ID, time, and condition parameters) and expressed as -ΔCT for relative 
change in expression.  Sample means that were greater than ± 2 standard deviations from 
the mean ΔCT, or ± 3 standard deviations from the mean ΔCT after exclusion, were 
considered outliers and removed from the analysis.  Of the 218 data points in 36 groups 
used in the analysis, only 14 data points were excluded according to this criteria, and no 
more than one data point in any individual experimental group was excluded.  Fold 
change in miRNA/mRNA expression was determined by calculating the difference 
between the mean ΔCTs of sham, morphine, and vehicle sample groups at the same time 
point (-ΔΔCT), and expressed as a baseline-corrected percentage of fold-change ([2-
ΔΔCT-1]*100). 
 
3.3.8 Data analysis 
All data were analyzed using SPSS software version 18 (SPSS; Chicago, IL).  
MicroRNA expression, verified by qRT-PCR, was analyzed by multivariate analysis of 
variance (ANOVA) using Pillai’s trace statistic, and further analyzed using post hoc 
univariate ANOVA and Fisher’s least significant difference (f-LSD) test.  Other data 
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were analyzed using ANOVAs followed by post hoc f-LSD using planned comparisons.  
In all cases, the a priori α value was set at 0.05.  Data were expressed as mean ±SEM, as 
indicated in the figure legends.  
Correlations between initial injury severity and either miRNA or IL6R mRNA 
expression, and between tail-flick latency and either miRNA or IL6R mRNA expression, 
were determined by Pearson’s product-moment correlation (PPMC) using –ΔCT values 
of either the miRNAs or IL6R, initial BBB scores, day 13 BBB scores, and tail-flick 
latency as separate independent variables.  All partial correlations were controlled for 
time only.  The a priori α value was set at 0.05, and data were expressed as the mean 
difference in cycle threshold change of either each miRNA relative to the cycle threshold 
of U6 controls (-ΔCT= CTU6 - CTmiRNA) or IL6R expression relative to the cycle 
threshold of GAPDH controls (-ΔCT= CTGAPDH - CTIL6R). 
 
3.4 Results 
3.4.1 Quantification of morphine-induced changes in miRNA expression  
We previously reported that miR1, miR21, miR124, miR129-2, and miR146a were 
significantly dysregulated following spinal cord contusion (Strickland et al., 2011).  To 
determine whether morphine treatment further dysregulates SCI-sensitive miRNAs, their 
expression was examined by qRT-PCR in sham controls and in response to vehicle and 
morphine treatment following contusion, at either 2 or 15 days post-SCI.  Multivariate 
ANOVA of qRT-PCR data indicated a significant main effect of time (Pillai’s Trace 
Statistic, F(5,19)=21.094; p<0.005) and treatment (F(10,40)=3.742; p<0.005), and a 
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significant interaction effect between time and treatment (F(10,40)=6.478; p<0.005).  Post 
hoc univariate ANOVAs indicated a main effect of treatment on miR21, miR129-2, and 
miR146a (F(2,23)=65.038; p<0.005, F(2,23)=17.265; p<0.005, and F(2,23)=16.163; p<0.005, 
respectively), and a significant interaction effect of time and treatment on miR21 and 
miR146a expression (F(2,23)=8.229; p<0.005 and F(2,23)=10.055; p<0.005, respectively).  
In addition, post hoc least significant difference (LSD) t-tests indicated that both miR21 
and miR146a expression is increased following spinal cord trauma, irrespective of 
morphine treatment (pmiR21<0.001 and pmiR146a<0.001; Figure 11a, b).  In contrast, 
miR129-2 expression was down-regulated following both morphine and vehicle 
administration (pmiR129-2<0.001 and pmiR129-2<0.001, respectively), and there was no 
change in the expression of either miR1 or miR124 (Figure 11a, b).  Post hoc planned 
comparisons indicated that there was a significant increase in expression of miR21 in 
response to morphine treatment relative to vehicle at 15 days post-SCI (Student’s two-
tailed t-test, p<0.05; Figure 11c, d).  In addition, Pearson’s product-moment correlations 
indicated a statistically significant correlation between miR21 expression and time 
(Pearson’s r=0.61, p<0.005).  Controlling for time, partial correlation analysis showed 
that miR21 expression was significantly correlated with the expression of miR1, 
miR124, and miR146a (Pearson’s r=0.51, p<0.03, Pearson’s r=0.58, p<0.01, and 
Pearson’s r=0.83, p<0.001, respectively). 
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Figure 11. Bar graphs depicting qRT-PCR analysis of miRNA expression of miR1, miR21, miR124, 
miR129-2, and miR146a at the lesion site for sham animals and after administration of either morphine or 
vehicle in contused animals at either 2 (a, c) or 15 (b, d) days post-SCI.  (a-b) The x-axis denotes miRNA 
of interest, and the y-axis denotes the mean change in cycle threshold, where ΔCT represents the mean 
difference of miRNA and U6 control ΔCT values.  Animals received either a laminectomy only (sham) or 
a T12-T13 spinal contusion followed by administration of vehicle or morphine 24 hrs later, and sacrificed 
at 2 or 15 days post-surgery for harvesting of the cords. Data are expressed relative to U6 controls (a value 
of zero equates to no difference in expression between the miRNA and U6, positive values equate to 
higher miRNA expression, and negative values vice versa), with asterisks indicating significance (f-LSD) 
compared with sham controls; p values are as indicated in the text.  (c-d) The x-axis denotes miRNA of 
interest, and the y-axis denotes the baseline-corrected percentage of fold expression change of miRNA 
using the formula (2-ΔΔCT-1)*100, where ΔΔCT represents the mean difference of contused vehicle and 
sham, contused morphine and sham, or contused morphine and contused vehicle ΔCT values.  Data are 
expressed as a percentage of change (a value of zero equates to no change between surgery conditions), 
with asterisks indicating significance (f-LSD) compared with sham controls and hash tags indicating 
significance (f-LSD) compared with contused vehicle controls; p values are as indicated in the text. 
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3.4.2 Impact of injury severity and functional recovery on miRNA expression 
We previously observed a significant relationship between the expression of both 
miR129-2 and miR146a and injury severity, as indicated by initial BBB scores following 
surgery.  Accordingly, we assessed whether this relationship would be replicated by the 
new data set.  Indeed, there was a statistically significant correlation between BBB 
scores at 24 hours post-SCI and the expression of both miR129-2 and miR146a across 
both time points (Pearson’s r=0.66, p<0.001 and Pearson’s r=-0.55, p<0.001, 
respectively; Figure 12a, b).  Contrary to our previous findings, we also found a 
statistically significant correlation between the expression of miR21 and initial BBB 
scores (Pearson’s r=-0.88, p<0.001; Figure 12c).  Additionally, we analyzed the 
relationship between recovery of function, as indicated by Day 13 BBB scores, and 
miRNA expression at 15 days post-SCI.  Similar to initial injury severity, there were 
statistically significant correlations between BBB scores at 13 days post-SCI and 
expression of miR129-2, miR146a, and miR21 (Pearson’s r=0.50, p<0.05, Pearson’s r=-
0.70, p<0.001, and Pearson’s r=-0.80, p<0.001, respectively; Figure 13a-c). 
 
3.4.3 Relationship between SCI-sensitive miRNA expression and sensory reactivity 
In order to assess the possibility that pain sensitivity is associated with the expression of 
SCI-sensitive miRNAs, thermal thresholds were measured by the tail flick-latency test, 
following SCI, both before and after treatment of morphine.  Accordingly, there were 
statistically significant correlations between baseline tail-flick latency and expression of 
miR1, miR124, and miR129-2 regardless of time point (Pearson’s r=0.41, p<0.05,  
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Figure 12. Correlation analysis to assess the relationship between miRNA expression and initial injury 
severity.  (a-c) The x-axis represents the Basso, Beattie, and Bresnahan (BBB) score for baseline 
locomotor function, 24 hours following spinal cord contusion, and the y-axis depicts the mean difference 
in cycle threshold change (-ΔCT) between miRNA expression at both 2 and 15 days post-SCI and U6 
controls.  Pearson’s product-moment correlations indicated a significant correlation between miR129-2 
(a), miR146a (b), and miR21 (c), and initial BBB score (Pearson’s r=0.66, P<0.001, Pearson’s r=-0.55, 
P<0.001, and Pearson’s r=-0.88, P<0.001, respectively).  Data are represented as the mean change in cycle 
threshold of miRNA expression relative to U6 controls (-ΔCT= CTU6 - CTmiRNA). 
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Figure 13. Correlation analysis to assess the relationship between miRNA expression and functional 
recovery.  (a-c) The x-axis represents the BBB score for locomotor function recorded 13 days following 
spinal cord contusion, and the y-axis depicts the mean difference in cycle threshold change (-ΔCT) 
between miRNA expression at 15 days post-SCI and U6 controls.  Pearson’s product-moment correlations 
indicated a significant correlation between miR129-2 (a), miR146a (b), and miR21 (c), and Day 13 BBB 
score (Pearson’s r=0.50, P<0.05, Pearson’s r=-0.70, P<0.001, and Pearson’s r=-0.80, P<0.001, 
respectively).  Data are represented as the mean change in cycle threshold of miRNA expression relative 
to U6 controls (-ΔCT= CTU6 - CTmiRNA). 
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Pearson’s r=0.43, p<0.05, and Pearson’s r=0.41, p<0.05, respectively; Figure 14a-c), 
and as predicted these correlations were abolished following morphine administration. 
 
3.4.4 Expression of miR-1 in vascular tissues following SCI 
We previously observed a significant decrease in miR1 expression following spinal cord 
contusion (Strickland et al., 2011), but did not find a significant change in expression 
following SCI and administration of the tail-flick test.  Given the positive correlation of 
miR1 expression with sensory reactivity and the capability of miR1 to inhibit 
angiogenesis (Stahlhut et al., 2012), added to the fact that miR1 is heavily expressed in 
the cardiovascular system (Fichtlscherer et al., 2011; Jakob and Landmesser, 2012), it is 
possible that the change in expression of miR1 at the injury site may represent a broader 
response of vascular and cardiac tissues to SCI.  We therefore assessed miR-1 
expression in heart and carotid arterial tissue.  Quantitative RT-PCR indicated that there 
was not a significant change in miR1 expression in either of these tissues following SCI 
(Figure 15), suggesting that the changes in miR-1 expression previously observed 
(Strickland et al., 2011) are localized within the injury site rather than due to adaptive 
changes in the peripheral vascular system.  
 
3.4.5 MiRNA regulation of pain neuro-circuitry associated cytokines 
As miR21 is further dysregulated following morphine administration, we assessed the 
extent to which changes in miR21 expression were associated with alterations in known 
cytokine mRNA targets.  MiR21 has previously been shown to regulate the interleukin-6  
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Figure 14.  Correlation analyses to assess the relationship between miRNA expression and sensory 
reactivity following SCI.  (a-c) The x-axis represents the mean difference in cycle threshold change (-
ΔCT) between miRNA expression at both 2 and 15 days post-SCI and U6 controls, and the y-axis depicts 
the baseline tail-flick latency for pain sensitivity assessed 24 hours following spinal cord contusion and 
prior to morphine or vehicle administration.  Pearson’s correlations indicated a significant correlation 
between miR1 (a), miR124 (b), and miR129-2 (c) and baseline tail-flick latency (Pearson’s r=-0.41, 
P<0.05, Pearson’s r=-0.43, P<0.05, and Pearson’s r=-0.41, P<0.05, respectively), but no significant 
correlations were found following vehicle or morphine administration.  Data are represented as the mean 
change in cycle threshold of miRNA expression relative to U6 controls (-ΔCT= CTU6 - CTmiRNA). 
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Figure 15. Bar graph depicting qRT-PCR analysis of miR1 expression in hearts and carotid arteries 
following SCI.  The x-axis denotes tissue of interest, and the y-axis denotes the mean change in cycle 
threshold, where ΔCT represents the mean difference of miR1 and U6 control ΔCT values.  Animals 
received either a laminectomy only (sham) or a T12-T13 spinal contusion, and were sacrificed 24 hrs post-
surgery for harvesting of the cords.  Data are expressed as measure of expression relative to U6 controls (a 
value of zero equates to no difference in expression between miR1 and U6, positive values equate to a 
higher expression of miR1, and negative values vice versa), and indicate that there was no significant 
change in miR1 expression between contused and sham groups, both in heart and carotid artery tissue 
(p<0.17 and p<0.14, respectively). 
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receptor, IL6R (Frankel et al., 2008).  To determine if IL6R was additionally 
dysregulated by alteration of pain neuro-circuitry, the expression of mRNA transcripts 
for IL6R was examined by qRT-PCR in sham controls and in response to vehicle and 
morphine treatment following contusion injury.  An ANOVA revealed a main effect of 
both time and treatment on IL6R mRNA (F(1,28)=4.533; p<0.05, and F(2,28)=10.881; 
p<0.01, respectively), and post hoc LSD t-tests indicated that IL6R expression is 
increased following spinal cord trauma, irrespective of morphine treatment (pContused 
Vehicle vs. Sham<0.0001 and pContused Morphine vs. Sham<0.001; Figure 16a, b).  In addition, there 
were significant correlations between IL6R mRNA expression and miR21, miR124, 
miR129-2, and miR146a (Pearson’s r=0.63, p<0.001, Pearson’s r=-0.38, p<0.05, 
Pearson’s r=-0.59, p<0.001, and Pearson’s r=0.57, p<0.001, respectively).  Partial 
correlations controlling for the effects of time also indicated that the expression of IL6R 
mRNA was significantly correlated with expression of both miR124 and miR146a 
(Pearson’s r=-0.54, p<0.05, and Pearson’s r=0.47, p<0.05, respectively).  Furthermore, 
IL6R expression was predictive of nociceptive sensitivity, as there was a statistically 
significant correlation between baseline tail-flick latency and IL6R expression across 
both time points (Pearson’s r=-0.585, p<0.01; Figure 17a), and this correlation was 
abolished following morphine administration.  Finally, there was a statistically 
significant correlation between BBB scores at 24 hours post-SCI and IL6R expression, 
indicating that variation in initial injury severity is predictive of variation in IL6R 
expression (Pearson’s r=0.656, p<0.01; Figure 17b), but there was not a significant 
correlation between day 13 BBB scores and IL6R mRNA expression (p=0.49). 
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Figure 16. Bar graphs depicting qRT-PCR analysis of mRNA expression of IL6R at the lesion site for 
sham animals and after administration of either morphine or vehicle in contused animals at 2 and 15 days 
post-SCI.  (a) The x-axis denotes time following surgery, and the y-axis denotes the mean change in cycle 
threshold, where ΔCT represents the mean difference of mRNA and GAPDH control ΔCT values.  
Animals received either a laminectomy only (sham) or a T12-T13 spinal contusion followed by 
administration of vehicle or morphine 24 hrs later, and sacrificed at 2 or 15 days post-surgery for 
harvesting of the cords. Data are expressed relative to GAPDH controls (a value of zero equates to no 
difference in expression between the miRNA and GAPDH, positive values equate to higher miRNA 
expression, and negative values vice versa), with asterisks indicating significance (f-LSD) compared with 
sham controls; p values are as indicated in the text.  (b) The x-axis denotes time after surgery, and the y-
axis denotes the baseline-corrected percentage of fold expression change of IL6R mRNA using the 
formula (2-ΔΔCT-1)*100, where ΔΔCT represents the mean difference of contused vehicle and sham, 
contused morphine and sham, or contused morphine and contused vehicle ΔCT values.  Data are expressed 
as a percentage of change (a value of zero equates to no change between surgery conditions), with 
asterisks indicating significance (f-LSD) compared with sham controls and hash tags indicating 
significance (f-LSD) compared with contused vehicle controls; p values are as indicated in the text. 
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Figure 17. Correlation analyses to assess the relationship between IL6R mRNA expression and sensory 
reactivity following SCI.  (a) The x-axis represents the mean difference in cycle threshold change (-ΔCT) 
between mRNA expression at both 2 and 15 days post-SCI and GAPDH controls, and the y-axis depicts 
the baseline tail-flick latency for pain sensitivity at 24 hours following spinal cord contusion and prior to 
morphine or vehicle administration.  Pearson’s product-moment correlations indicated a significant 
correlation between IL6R and baseline tail-flick latency (Pearson’s r=0.59, P<0.01), but no significant 
correlations were found following vehicle or morphine administration.  Data are represented as the mean 
change in cycle threshold of mRNA expression relative to GAPDH controls (-ΔCT= CTGAPDH - CTIL6R).  
(b) The x-axis represents the BBB score for baseline locomotor function, 24 hours following spinal cord 
contusion, and the y-axis depicts the mean difference in cycle threshold change (-ΔCT) between IL6R 
mRNA expression at both 2 and 15 days post-SCI and GAPDH controls.  Pearson’s product-moment 
correlations indicated a significant correlation between IL6R expression and initial BBB score (Pearson’s 
r=-0.66, P<0.01).  Data are represented as the mean change in cycle threshold of miR21 expression 
relative to GAPDH controls (-ΔCT= CTGAPDH - CTIL6R). 
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3.5 Discussion 
Morphine treatment plays an important role in pain mitigation in both the acute and 
chronic phase of spinal cord trauma. However, its deleterious effects on functional 
recovery and exacerbation of chronic pain systems, through activation of innate immune 
responses, provide a substantial challenge towards clinical efforts to minimize the short 
and long term effects of SCI (Dworkin et al., 2003; McCarberg, 2004; Watkins et al., 
2005; Hook et al., 2007; Scholz and Woolf, 2007; Watkins et al., 2007; Hook et al., 
2009; Hook et al., 2011).  Given their dysregulation following SCI and ability to 
coordinate the expression of large gene networks, it is likely that miRNAs are involved 
in SCI-induced remodeling of nociceptive circuitry, and consequently, the effects of 
opiates like morphine on this circuitry.  Therapeutic manipulation of these miRNAs 
could attenuate the maladaptive effects of acute morphine administration on both the 
acute and chronic phases of SCI by suppressing activation of inflammation and 
inhibiting the synaptic remodeling that increases both neuropathic pain and morphine 
tolerance. 
 In the current study, we investigated the regulation of SCI-sensitive miRNAs 
following morphine treatment.  Specifically, we replicated our previous observation that 
miR129-2 is decreased following spinal cord contusion, while miR21 and miR146a were 
induced, irrespective of morphine treatment (Strickland et al., 2011).  Interestingly, in 
this study, neither miR1 nor miR124 were significantly altered in SCI animals. One 
possible explanation that merits further investigation is that the measurement of pain 
sensitivity itself exposed SCI animals to nociceptive stimuli, which may have 
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normalized miR1 and miR124 expression. This possibility is supported by reports 
showing that peripheral inflammation, which is also known to trigger nociception, 
results in persistent elevation in miR1 in the dorsal horn of the spinal cord (Kusuda et 
al., 2011).  Additionally, both miR1 and miR124 are predicted to play a central role in 
the late phase gene repression associated with long-term potentiation-dependent 
neuronal plasticity (Ryan et al., 2012), and therefore, the normalization of these miRNAs 
may be important for activation of neural circuitry associated with pain as well.  
We found that morphine exposure significantly induced miR21 expression and 
resulted in a near-significant increase in miR146a expression 15 days after SCI. This is 
the first evidence for the potential involvement of miRNAs and consequently, miRNA-
regulated gene networks, as mediators of morphine’s effects on plasticity in the spinal 
cord following SCI.  In addition, changes in expression of miR21 were significantly 
explained by the variance in expression of miR1, miR124, and miR146a, suggesting that 
these miRNAs may be co-regulated.  Moreover, while the expression of miR21 and 
miR146a was significantly correlated with locomotor behavioral performance following 
SCI, their expression did not predict pain sensitivity.  Consequently, the induction of 
these miRNAs by morphine is unlikely to be related to the analgesic actions of 
morphine, but rather, to its pro-inflammatory actions.  Several lines of evidence support 
this hypothesis.  Firstly, the expression of both miR146a and miR21 is induced by pro-
inflammatory cytokines (Taganov et al., 2006; Loffler et al., 2007; O'Connell et al., 
2007; Tili et al., 2007; Nakasa et al., 2008), and reciprocally, both miRNAs target 
mRNA transcripts of pro-inflammatory cytokines or their receptors (Frankel et al., 2008; 
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Nahid et al., 2009; Li et al., 2010a).  Secondly, both miR21 and miR146a play an 
important role in the innate immune response (Taganov et al., 2006; Moschos et al., 
2007; Nahid et al., 2009; Li et al., 2010a; Li et al., 2010b), because increased expression 
of both miR21 and miR146a negatively regulates innate immune signaling.  Finally, 
miR21 and miR146a have been found to be highly expressed in activated astrocytes, and 
their over expression results in attenuation of astrocytic hypertrophy and suppression of 
the astrocyte-mediated inflammation response, respectively (Bhalala et al., 2012; Iyer et 
al., 2012).  As a result, it is more likely that these miRNAs serve as a component of 
morphine-induced inflammation rather than being involved in the morphine-triggered 
signaling cascade driving analgesia.  
Interestingly, we observed that although the interleukin receptor IL6R was 
dysregulated following SCI, it was not additionally dysregulated by morphine 
administration.  Moreover, contrary to our prediction, the transcript for IL6R, the 
identified miR21 target, was persistently up-regulated following SCI, suggesting a 
dissociation between miRNA and target gene networks following SCI, as has been 
observed in other models of neural damage (Pappalardo et al., 2013).  Indeed, changes in 
expression of IL6R were significantly explained by the variance in miR21, miR124, 
miR129-2, and miR146a, suggesting that regulation of IL6R involves a network of 
miRNAs rather than any single miRNA.  We also observed that variations in IL6R 
mRNA expression explained a statistically significantly portion of the variance in initial 
injury severity, suggesting that decreased expression of IL6R, and presumably lower 
levels of inflammation, was associated with a less severe initial injury.  Indeed, this 
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relationship is likely to be causal in nature, because application of an anti-IL6R antibody 
immediately after injury has been shown to significantly decrease tissue damage, 
increase axonal regeneration, and improve functional recovery (Mukaino et al., 2010).  
Finally, since variability in IL6R mRNA expression also explained a statistically 
significant proportion of the variability in pain sensitivity (58.5%), it is possible that 
IL6R also plays a significant role in remodeling inflammation-driven pain neuro-
circuitry following SCI and opiate exposure.   
 We were able to reaffirm our previous finding that expression changes of both 
miR129-2 and miR146a were significantly explained by the variance of initial injury 
severity (Strickland et al., 2011).  In addition, we found that fluctuations in miR21 
expression were significantly explained by the variance in BBB scores 24 hours post-
SCI, and that changes in miR129-2, miR146a, and miR21 were also significantly 
explained by the variance in functional recovery at 13 days post-SCI.  Similar to 
miR146a, miR21 is a negative regulator of inflammation, but it also has anti-apoptotic 
activity (Sathyan et al., 2007; Roy and Sen, 2011).  As such, its up-regulated expression 
may result in increased neuronal survival following SCI by inhibiting inflammation and 
cell death, factors which are likely to result in better locomotor function and higher 
initial BBB scores.  One therapeutically relevant prediction from these data that merits 
further investigation is that application of miR21 or miR146a mimetics prior to or 
concurrent with morphine administration in the acute phase of SCI may attenuate opioid 
mediated inflammation, and could also reduce apoptosis (protecting the potential for 
recovery) in this early phase of injury. 
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 Finally, we observed that miRNA expression at the injury site explained a 
significant proportion of the sensitivity to nociceptive stimuli, i.e., the response of 
sensorimotor circuitry distal to the injury site.  Not surprisingly, these correlations 
between pain sensitivity and miRNA expression were abrogated by morphine 
administration, due to the analgesic effects of morphine. While these correlations do not 
necessarily imply causality, they do advance the possibility that there is a degree of 
molecular integration between the injury site and more caudal, but anatomically intact 
neuro-circuitry.  A mechanism for cross-talk between miRNAs at the injury site and 
caudal neuro-circuitry is unclear at this time, but the possibility that these interactions 
serve an adaptive function is intriguing, and needs further investigation.  
 
3.6 Conclusion 
Our evidence shows that acute morphine administration results in a very specific and 
limited profile of changes in SCI-sensitive miRNA expression during the chronic phase 
of injury.  Interestingly, expression changes are confined to miRNAs, like miR21, that 
are both induced by and inhibitors of pro-inflammatory cytokines, suggesting that 
morphine may potentially interfere with miRNA-mediated negative feedback pathways. 
Like miR21, IL6R mRNA was persistently up-regulated after SCI, and its expression 
negatively correlated with initial injury severity, suggesting that IL6R and miR21 may 
be a coordinately regulated, adaptive response to SCI.  Furthermore, miR1, miR124, and 
miR129-2 expression at the injury site appears to play a substantial role in the regulation 
of distal nociceptive signaling pathways.  Collectively, these data suggest that SCI-
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sensitive miRNAs constitute an important component of emerging pain-sensitivity and 
inflammation, and consequently, these miRNAs could serve as therapeutic targets 
following SCI.  
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4. REGULATORY EFFECTS OF INTERMITTENT NOXIOUS STIMULATION ON 
SPINAL CORD INJURY-SENSITIVE MICRORNAS AND THEIR PRESUMPTIVE 
TARGETS FOLLOWING SPINAL CORD CONTUSION 
 
4.1 Overview 
Chronic pain is a common consequence of spinal cord injury (SCI), and uncontrollable 
nociception due to peripheral tissue damage below the level of the lesion site can 
sensitize spinal neurons and lead to the development of neuropathic pain.  Previous 
studies indicated that SCI results in the induction and suppression of several microRNAs 
(miRNAs) at both the site of lesion, and in regions distal to the injury site.  We 
hypothesized that SCI-sensitive miRNAs would also be dysregulated by uncontrollable 
nociception, and that their expression may regulate gene targets important for the 
progression of maladaptive plasticity and hypersensitivity.  Our data indicated that 
intermittent noxious stimulation decreased expression of miR124 in dorsal tissue during 
the acute phase of injury and induced expression of miR129-2 in dorsal tissue and miR1 
in ventral tissue during the chronic phase of injury, suggesting that uncontrollable 
nociception distal to the injury site can affect specific regulatory changes in gene 
networks within sensorimotor circuitry of the lesion site.  We also found that 
uncontrollable nociception significantly down-regulated brain-derived neurotrophic 
factor (BDNF) expression 24 hrs after uncontrollable tailshock, and that expression of 
insulin growth factor-1 (IGF-1) was significantly induced at both 24 hrs and 7 days. 
Expression changes in IGF-1 mRNA expression were significantly explained by the 
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variance in miR124, miR21, and miR146a, while changes in BDNF mRNA expression 
were significantly explained by the variance in miR21 and miR124 expression, 
suggesting that both BDNF and IGF-1 regulation involves a network of miRNAs.  
Contrary to predictions, changes in neither BDNF nor IGF-1 expression, identified 
targets of miR1, were associated with variances in miR1 expression, indicating 
dissociation between miRNA and target gene expression.  Collectively, these data 
suggest that SCI-sensitive miRNAs may constitute therapeutic targets for attenuating 
increased glial activation and progression of neuropathic pain after SCI. 
 
4.2 Introduction 
Spinal cord injury (SCI) can cause a variety of debilitating consequences, including a 
loss of motor control, paralysis, and pain.  Uncontrollable nociception associated with 
concomitant peripheral tissue injury following SCI is particularly problematic, as the 
noxious stimulation results in increased glial activity (Frei et al., 2000; Hains and 
Waxman, 2006; Detloff et al., 2008) and sensitization of spinal neurons (Hains et al., 
2003; Lampert et al., 2006) that drives maladaptive spinal plasticity, impaired behavioral 
recovery, pain hypersensitivity, excito-toxicity, and cell death (Liu et al., 1999; Beattie 
et al., 2002; Xu et al., 2004; Kuzhandaivel et al., 2011).  Accordingly, we previously 
reported that intermittent noxious stimulation delayed the recovery of bladder function, 
led to greater mortality and spasticity, and increased tissue loss at the injury site in adult 
rats (Grau et al., 2004).  In addition, we found that nociceptive stimulation at 24 hrs 
resulted in decreased brain-derived neurotrophic factor (BDNF)-tropomyosin-receptor 
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kinase (TrkB) signaling (Gomez-Pinilla et al., 2007; Garraway et al., 2011), and this 
signaling pathway has been shown to play a key role in modulating neuronal plasticity, 
promoting axonal regeneration, and improving functional recovery following SCI (Xu et 
al., 1995; Patterson et al., 1996; McTigue et al., 1998; Kerr et al., 1999; Garraway et al., 
2003; Boyce et al., 2007).   
 Despite the importance of uncontrollable nociception to recovery from SCI, there 
is limited knowledge of the effects of nociception on mechanisms that may ultimately 
influence neurotrophic signaling pathways and functional recovery. Our previous data 
showing that a network of miRNAs was altered following SCI suggested a hypothesis 
that these molecules may also be sensitive to nociceptive stimuli following SCI, 
resulting in activation of potentially mal-adaptive gene networks.  MiRNAs are short, 18 
to 25 nucleotide-long non-coding small RNAs that play an important regulatory role in 
gene expression by inhibiting protein translation or targeting mRNA transcripts for 
degradation (Alvarez-Garcia and Miska, 2005; Zamore and Haley, 2005).  Individual 
miRNAs are able to coordinate gene networks to affect a specific cellular endpoint by 
simultaneously controlling expression of several hundred mRNAs.  Additionally, not 
only have miRNAs been shown to play a major role in neurodegenerative diseases (Kim 
et al., 2007; Hebert et al., 2008; Hebert and De Strooper, 2009; Numakawa et al., 2011), 
but they also regulate BDNF expression in the brain (Mellios et al., 2008) and inhibit its 
expression in neurodegenerative disease states like Alzheimer’s disease (Lee et al., 
2012). 
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 We and other groups have previously shown that SCI is followed by 
dysregulated miRNA expression (Liu et al., 2009; Nakanishi et al., 2010; Strickland et 
al., 2011).  Our previous study showed that miR1, miR124, and miR129 were 
significantly down-regulated following spinal cord contusion, with miR146a and miR21 
transiently induced (Strickland et al., 2011).  In addition, changes in both miR129-2 and 
miR-146a expression significantly explained the variability in injury severity.  
Interestingly, miR1, a member of the miR1/miR206 family has been shown to regulate 
important growth-promoting neurotrophic factors like BDNF (Lewis et al., 2003; Lee et 
al., 2012) and insulin growth factor-1 (IGF-1; Yu et al., 2008; Li et al., 2012).  
Moreover, increased expression of IGF-1 has been associated with increased spasticity 
of skeletal muscle following SCI (Gorgey and Gater, 2012).  Consequently, miR1 and 
other SCI-sensitive miRNAs may be further dysregulated following intermittent noxious 
stimulation, and play an important role in regulating critical gene networks involved in 
the maladaptive spinal cord plasticity that results in hypersensitivity and impaired 
functional recovery.  To assess these possibilities, the current study investigated the 
relationship between SCI-sensitive miRNA expression and intermittent noxious 
stimulation at 1 hour, 24 hours, and 7 days post-SCI.  Likewise, we also assessed the 
relationship between the expression of miRNAs sensitive to intermittent noxious 
stimulation and that of their mRNA targets. 
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4.3 Experimental Procedures 
4.3.1 Subjects 
The subjects were male Sprague–Dawley rats (Rattus norvegicus) obtained from Harlan 
(Houston, TX). The rats were approximately 90-110 days old (350-400 g), individually 
housed in Plexiglas bins [45.7 (length) x 23.5 (width) x 20.3 (height) cm] with food and 
water continuously available, and maintained on a 12 hour light/dark cycle.  All 
behavioral testing was performed during the light cycle.  To facilitate access to the food 
and water, extra bedding was added to the bins after surgery and long mouse sipper 
tubes were used so that the rats could reach the water without rearing.  All of the 
experiments were reviewed and approved by the institutional animal care committee at 
Texas A&M University and all NIH guidelines for the care and use of animal subjects 
were followed. 
 
4.3.2 Surgery 
Subjects were anesthetized with isoflurane (5%, gas). Once a stable level of anesthesia 
was achieved, the concentration of isoflurane was lowered to 2-3%.  An area extending 
approximately 4.5 cm above and below the injury site was shaved and disinfected with 
iodine, and a 7.0 cm incision was made over the spinal cord.  Next, two incisions were 
made on either side of the vertebral column, extending about 3 cm rostral and caudal to 
the T12-T13 segment.  The dorsal spinous processes at T12-T13 were removed 
(laminectomy), and the spinal tissue exposed.  The dura remained intact.  For the 
contusion injury, the vertebral column was fixed within the MASCIS device (Gruner, 
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1992; Constantini and Young, 1994), and a moderate injury was produced by allowing 
the 10 g impactor (outfitted with a 2.5 mm tip) to drop 12.5 mm.  Sham controls 
received a laminectomy, but the cord was not contused with the MASCIS device.  
Following surgery, the wound was closed with Michel clips.  T12-T13 level contusion 
models have been routinely used by members of our group to define spinal cord learning 
circuits and molecular mechanisms involved with recovery of function (Ferguson et al., 
2008; Brown et al., 2011; Hook et al., 2011).  Lesions at this level result in well-defined 
and replicable sensory-motor deficits, and we therefore chose to utilize contusion at this 
level to also examine changes in miRNA expression. 
To help prevent infection, subjects were treated with 100,000 units/kg Pfizerpen 
(penicillin G potassium) immediately after surgery and again 2 days later.  For the first 
24 hours after surgery, rats were placed in a recovery room maintained at 26.6 0 C.  To 
compensate for fluid loss, subjects were given 2.5 ml of saline after surgery.  Bladders 
were manually expressed twice daily (morning and evening) until the animals had empty 
bladders for three consecutive days, at the times of expressing.  
  
4.3.3 Uncontrollable intermittent noxious stimulation 
Intermittent shock to the tail was applied to subjects as previously described (Garraway 
et al., 2011).  Subjects were treated with electrical stimulation 24 hours after surgery 
(modified from Washburn et al., 2007), and were loosely restrained in Plexiglas tubes 
also as previously described (Crown et al., 2002; Grau et al., 2004).  Electrical 
stimulation was applied to the tail using an electrode gel (Harvard Apparatus, Holliston, 
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MA, USA) and attached 2 cm from the tip of the tail with Orthaleic tape.  Leads from 
the fuse clip were attached to a BRS/LVE shock generator (Model SG-903), and 
intermittent constant current 1.5 mA, AC (60 Hz) electrical stimulus was applied 
through the electrodes.  Rats treated with uncontrollable intermittent stimulation 
received 180, 80-ms tail shocks on a variable time schedule with a mean inter-stimulus 
interval of 2 seconds (range 0.2-3.8 s).  Unshocked subjects were placed in the 
restraining tubes for an equal amount of time as shock subjects, had the electrodes 
attached, but did not receive the electrical stimuli.    
 
4.3.4 RNA extraction and qRT-PCR  
Animals were sacrificed at 1 hr, 24 hrs, or 7 days following SCI/unshocked (SCIunshock) 
or SCI/shock-exposed (SCIshock) treatment.  All subjects were deeply anesthetized with 
pentobarbital (50 mg/kg), and 1 cm of spinal cord around the lesion epicenter was 
rapidly removed.  To determine the spatial (dorsal-ventral) changes in the expression of 
miRNAs and genes of interest, the spinal cord tissue was further sectioned to yield 
dorsal and ventral portions in the 24 hrs and 7 days after treatment groups.  The cord was 
processed for the extraction of total RNA (RNeasy Mini Kit; Qiagen, Valencia, CA, 
USA), quantified using a NanoDrop 2000 Spectrophotometer (Thermo Scientific; 
Wilmington, DE), and stored at -80 °C. 
MiRNA expression data was measured with quantitative reverse transcription 
(qRT)-PCR for miRNAs, based on the protocol of the miRCURYTM LNA microRNA 
Universal RT-PCR system (EXIQON; Woburn, MA).  RNA samples were converted to 
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cDNA, and qRT-PCR was performed using a 7900HT Fast Real-Time PCR System 
(Applied Biosystems, Foster City, CA).  Forward and reverse primers (EXIQON; 
Woburn, MA) for hsa-miR124, hsa-miR1, hsa-miR21, hsa-miR129-2, and hsa-miR146a 
were used for PCR amplification, and real time data was normalized using U6 RNA.  
Similarly, messenger RNA (mRNA) expression of brain-derived neurotrophic factor 
(BDNF) and insulin growth factor-1 (IGF-1) was measured using qRT-PCR for mRNAs, 
based on the protocol for PerfeCTa® SYBR® Green SuperMix with ROX™ (Quanta 
Biosciences; Gaithersburg, MD).  RNA samples were converted to cDNA using 
qScript™ cDNA SuperMix (Quanta Biosciences; Gaithersburg, MD), and qRT-PCR was 
performed using a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster 
City, CA).  Forward and reverse primers (Integrated DNA Technologies; Coralville, IA) 
for BDNF and IGF-1 were used for PCR amplification, and real time data was 
normalized using glyceraldehyde 3-phosphate dehydrogenase (GAPDH).  Relative 
miRNA and mRNA expression was determined by calculating the mean difference 
between cycle threshold of either the miRNA from the U6 small nuclear RNA (U6SNB) 
normalized control, or the BDNF/IGF-1 mRNA from the GAPDH normalized control 
for each sample [Δ cycle threshold (ΔCT)] within each sample group (samples with 
same miRNA ID, time, and condition parameters) and expressed as -ΔCT for relative 
change in expression.  Sample means that were greater than ± 2 standard deviations from 
the mean ΔCT, or ± 3 standard deviations from the mean ΔCT after exclusion, were 
considered outliers and removed from the analysis.  Of the 560 data points in 105 groups 
used in the analysis, only 30 data points were excluded according to this criteria, and no 
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more than one data point in any individual experimental group was excluded.  Fold 
change in miRNA/mRNA expression was determined by calculating the difference 
between the mean ΔCTs of sham, SCI/unshocked (SCIunshock), and SCI/shock-exposed 
(SCIshock) sample groups at the same time point (-ΔΔCT), and expressed as a baseline-
corrected percentage of fold-change ([2-ΔΔCT-1]*100). 
 
4.3.5 Data analysis 
All data were analyzed using SPSS software version 18 (SPSS; Chicago, IL).  
MicroRNA expression, verified by qRT-PCR, was analyzed by multivariate analysis of 
variance (ANOVA) using Pillai’s trace statistic, and further analyzed using post hoc 
univariate ANOVA and Fisher’s least significant difference (f-LSD) test.  Other data 
were analyzed using ANOVAs followed by post hoc f-LSD using planned comparisons.  
In all cases, the a priori α value was set at 0.05.  Data were expressed as mean ±SEM, as 
indicated in the figure legends. 
 
4.4 Results 
4.4.1 Quantification of shock-induced changes in miRNA expression 
4.4.1.1 Uncontrollable nociception had no significant effect on SCI-sensitive 
miRNAs 1 hr following treatment 
We previously reported that miR1, miR21, miR124, miR129-2, and miR146a were 
significantly dysregulated following spinal cord contusion (Strickland et al., 2011).  To 
determine whether uncontrollable intermittent noxious stimulation further dysregulates 
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SCI-sensitive miRNAs, their expression was determined by qRT-PCR in sham controls 
and in contused animals following either no shock exposure (SCIunshock) or 
uncontrollable intermittent tailshock (SCIshock).  Initially, we analyzed miRNA 
expression within the whole spinal cord segment (combined dorsal and ventral spinal 
cord) at the lesion site at 1 hr following intermittent noxious stimulation.  Planned 
comparisons indicated that there was a significant increase in expression of both miR21 
(Student’s two-tailed t-test, pUnshock<0.005 and pShock<0.001) and miR146a (Student’s 
two-tailed t-test, pUnshock<0.05 and pShock<0.005) following SCI, irrespective of shock or 
unshock treatment (Figure 18a, b). 
 
4.4.1.2 Multivariate ANOVA and post hoc univariate ANOVAs indicated a 
significant interaction effect of time, treatment, and spinal section on SCI-sensitive 
miRNA expression   
In subsequent experiments, we further microdissected the spinal cord tissue at the injury 
segment to yield dorsal/sensory and ventral/motor sections in the 24 hrs and 7 days 
treatment groups to assess spatial (dorsal-ventral) and functionally (sensory-motor)-
associated changes in SCI-sensitive miRNA expression.  We hypothesized that SCI-
induced expression changes of some trauma-sensitive miRNAs would exhibit spatial and 
functional specificity, and that uncontrollable nociception might exacerbate these 
changes.  Multivariate ANOVA of qRT-PCR data indicated a significant main effect of 
time (Pillai’s Trace Statistic, F(5,33)=20.888; p<0.001), treatment (F(10,68)=6.441; 
p<0.001), and spinal section (F(5,33)=8.312; p<0.001), and a significant interaction effect  
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Figure 18. Bar graphs depicting qRT-PCR analysis of miRNA expression of miR1, miR21, miR124, 
miR129-2, and miR146a at the lesion site for sham animals and after unshocked or shock treatment in 
contused animals at 1 hr following tailshock treatment.  (a) The x-axis denotes miRNA of interest, and the 
y-axis denotes the mean change in cycle threshold, where ΔCT represents the mean difference of miRNA 
and U6 control ΔCT values.  Animals received either a laminectomy only (sham) or a T12-T13 spinal 
contusion followed by administration of unshock or shock 24 hrs later, and sacrificed at 1 hr following 
unshock/shock treatment for harvesting of the cords. Data are expressed relative to U6 controls (a value of 
zero equates to no difference in expression between the miRNA and U6, positive values equate to higher 
miRNA expression, and negative values vice versa), with asterisks indicating significance (f-LSD) 
compared with sham controls; p values are as indicated in the text.  (b) The x-axis denotes miRNA of 
interest, and the y-axis denotes the baseline-corrected percentage of fold expression change of miRNA 
using the formula (2-ΔΔCT-1)*100, where ΔΔCT represents the mean difference of contused unshocked and 
sham, contused shocked and sham, or contused shocked and contused unshocked ΔCT values.  Data are 
expressed as a percentage of change (a value of zero equates to no change between surgery conditions), 
with asterisks indicating significance (f-LSD) compared with sham controls and hash tags indicating 
significance (f-LSD) compared with contused unshocked controls; p values are as indicated in the text. 
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between both time and treatment (F(10,68)=2.592; p<0.01), as well as a three-way 
statistically significant interaction between time, treatment, and spinal section 
(F(10,68)=2.594; p<0.01).  Post hoc univariate ANOVAs indicated a main effect of time 
on miR1, miR21, miR124, and miR146a (F(1,37)=27.562; p<0.001, F(1,37)=34.516; 
p<0.001, F(1,37)=16.025; p<0.001, and F(1,37)=108.342; p<0.001, respectively), a main 
effect of treatment on miR1, miR21, miR124, and miR129-2 (F(2,37)=11.803; p<0.001, 
F(2,37)=23.76; p<0.001, F(2,37)=17.493; p<0.001, and F(2,37)=14.774; p<0.001, 
respectively), and a main effect of spinal section on miR1 and miR146a (F(1,37)=10.58; 
p<0.005 and F(1,37)=9.137; p<0.005, respectively).  There was also a significant 
interaction effect of time and treatment on miR124 expression (F(2,23)=4.866; p<0.05), 
and of time, treatment, and spinal section on miR1, miR129-2, and miR146a 
(F(2,23)=3.68; p<0.05, F(2,23)=6.31; p<0.005, and F(2,23)=4.542; p<0.05, respectively). 
 
4.4.1.3 Uncontrollable nociception further dysregulated expression of the SCI-
sensitive miRNAs miR1, miR124, and miR129-2   
In addition, post hoc least significant difference (LSD) t-tests indicated that miR1, 
miR124, and miR129-2 expression is significantly decreased following spinal cord 
trauma, irrespective of exposure to uncontrollable intermittent tailshock (pmiR1<0.001, 
pmiR124<0.001, and pmiR129-2<0.001; Figure 19a-d).  In contrast, miR21 expression was 
up-regulated following both no shock exposure and uncontrollable intermittent tailshock 
(pmiR21<0.001), and there was no change in the expression of miR146a (Figure 19a-d).  
In response to uncontrollable intermittent tailshock relative to no shock exposure, post  
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Figure 19. Bar graphs depicting qRT-PCR analysis of miRNA expression of miR1, miR21, miR124, 
miR129-2, and miR146a in dorsal (a, c) and ventral (b, d) sections at the lesion site for sham animals and 
after unshocked or shock treatment in contused animals at either 24 hrs (a, b) or 7 days (c, d) following 
tailshock treatment.  (a-d) The x-axis denotes miRNA of interest, and the y-axis denotes the mean change 
in cycle threshold, where ΔCT represents the mean difference of miRNA and U6 control ΔCT values.  
Animals received either a laminectomy only (sham) or a T12-T13 spinal contusion followed by 
administration of unshock or shock 24 hrs later, and sacrificed at either 24 hrs or 7 days following 
unshock/shock treatment for harvesting and spatial sectioning of the cords. Data are expressed relative to 
U6 controls (a value of zero equates to no difference in expression between the miRNA and U6, positive 
values equate to higher miRNA expression, and negative values vice versa), with asterisks indicating 
significance (f-LSD) compared with sham controls; p values are as indicated in the text. 
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hoc planned comparisons indicated that there was a significant increase in expression of 
both miR1 in ventral/motor tissue and miR129-2 in dorsal/sensory tissue at 7 days 
following SCIunshock or SCIshock treatment (Student’s two-tailed t-test, p<0.05 and p<0.05, 
respectively), and a significant decrease in expression of miR124 in dorsal/sensory tissue 
at 24 hrs following SCIunshock or SCIshock treatment (p<0.01; Figure 20a-d).   Post hoc 
planned comparisons also indicated significant spatial changes (dorsal/sensory relative to 
ventral/motor) in miRNA expression, including decreased expression of both miR1 and 
miR146a in sham treated subjects at 24 hrs following SCIunshock or SCIshock treatment 
(p<0.005 and p<0.05, respectively), increased expression of miR124 in SCIunshock 
subjects at 24 hrs following SCIunshock or SCIshock treatment (p<0.01), decreased 
expression of miR1 in SCIshock subjects at 7 days following SCIunshock or SCIshock 
treatment (p<0.05), and decreased expression of miR146a in SCIunshock subjects at 7 days 
following SCIunshock or SCIshock treatment (p<0.05; Figure 21a, b).   
  
4.4.1.4 Correlation analyses indicated significant relationships between expression 
changes within distinct groups of SCI-sensitive miRNAs 
Given their dysregulation following both contusion injury and uncontrollable 
nociception, we also hypothesized that statistical relationships might exist between 
expression changes of different SCI-sensitive miRNAs, indicative of possible co-
regulation. Pearson’s product-moment correlations indicated three groups of significant 
correlations between miRNAs (Fig. 22a, b; Table 2).  There were significant correlations 
between miR1 and miR21, miR124, miR129-2, and miR146a (Pearson’s r=0.28, p<0.05,  
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Figure 20. Bar graphs depicting qRT-PCR analysis of percent fold change in miRNA expression of miR1, 
miR21, miR124, miR129-2, and miR146a in dorsal (a, c) and ventral (b, d) sections at the lesion site for 
sham animals and after unshocked or shock treatment in contused animals at either 24 hrs (a, b) or 7 days 
(c, d) following tailshock treatment.  (a-d) The x-axis denotes miRNA of interest, and the y-axis denotes 
the baseline-corrected percentage of fold expression change of miRNA using the formula (2-ΔΔCT-1)*100, 
where ΔΔCT represents the mean difference of contused unshocked and sham, contused shocked and 
sham, or contused shocked and contused unshocked ΔCT values.  Data are expressed as a percentage of 
change (a value of zero equates to no change between surgery conditions), with asterisks indicating 
significance (f-LSD) compared with sham controls and hash tags indicating significance (f-LSD) 
compared with contused unshocked controls; p values are as indicated in the text. 
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Figure 21. Bar graphs depicting qRT-PCR analysis of percent fold change in miRNA expression of miR1, 
miR21, miR124, miR129-2, and miR146a in dorsal sections relative to ventral at the lesion site for sham 
animals and after unshocked or shock treatment in contused animals at either 24 hrs (a) or 7 days (b) 
following tailshock treatment.  (a, b) The x-axis denotes miRNA of interest, and the y-axis denotes the 
baseline-corrected percentage of fold expression change of miRNA using the formula (2-ΔΔCT-1)*100, 
where ΔΔCT represents the mean difference of dorsal and ventral ΔCT values for each treatment (ΔCT 
represents the mean difference of miRNA and U6 control ΔCT values).  Data are expressed as a 
percentage of change (a value of zero equates to no change between spinal sections), with asterisks 
indicating significance (f-LSD) compared with ventral expression; p values are as indicated in the text. 
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Figure 22. Correlation analyses to assess the relationship between miR146a miRNA expression and 
expression of miR1, miR21, and miR124 following SCI.  (a) The x-axis and depth-axis represent the 
miRNAs of interest, and the y-axis depicts the magnitude of the Pearson’s product-moment correlation 
coefficient, r, between corresponding the miRNAs indicated on the x and depth axes.  Pearson’s 
correlations indicated 7 statistically significant relationships (p<0.05; black bars) and 3 non-significant 
relationships (p>0.05; white bars). (b) The x-axis represents the mean difference in cycle threshold change 
(-ΔCT) between miRNA expression at both 24 hrs and 7 days following tailshock treatment and U6 
controls, and the y-axis depicts the mean difference in cycle threshold change (-ΔCT) between miR146a 
expression at both 24 hrs and 7 days following tailshock treatment and U6 controls.  Pearson’s correlations 
indicated a significant correlation between miR1 (black diamonds), miR21 (white squares), and miR124 
(grey triangles), and miR146a (Pearson’s r=0.59, P<0.001, Pearson’s r=0.69, P<0.001, and Pearson’s 
r=0.39, P<0.005, respectively).  Data are represented as the mean change in cycle threshold of miRNA 
expression relative to U6 controls (-ΔCT= CTU6 - CTmiRNA). 
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Table 2.  Pearson’s product-moment correlations for miRNA expression at 24 hrs and 7 days following 
tailshock treatment.  For each correlation between miRNAs given by row and column heading, the 
Pearson’s Correlation Coefficient, r, the p value based on Student’s two-tailed t-test, and the sample 
number, N, are listed in order from top to bottom, respectively.  Three main clusters of miRNAs correlate 
significantly together: miR1 correlates with miR21, miR124, miR129-2, and miR146a, miR124 correlates 
with miR1, miR129-2, and miR146a, and miR146a correlates with miR1, miR21, and miR124.  Single 
asterisks denote a significance of p<0.05, and double asterisks denote a significance of p<0.01. 
    miR1 miR21 mir124 miR129-2 miR146a 
miR1 
Pearson 
Correlation   .282* .575** .349** .589** 
 Sig. (2-tailed)  0.034 0.001 0.01 0.001 
  N   57 54 54 54 
miR21 
Pearson 
Correlation .282*  0.163 -0.155 .691** 
 Sig. (2-tailed) 0.034  0.227 0.255 0.001 
 N 57  57 56 57 
mir124 
Pearson 
Correlation .575** 0.163   .742** .394** 
 Sig. (2-tailed) 0.001 0.227  0.001 0.003 
  N 54 57   57 56 
miR129-2 
Pearson 
Correlation .349** -0.155 .742**  0.021 
 Sig. (2-tailed) 0.01 0.255 0.001  0.876 
 N 54 56 57  56 
miR146a 
Pearson 
Correlation .589** .691** .394** 0.021   
 Sig. (2-tailed) 0.001 0.001 0.003 0.876  
  N 54 57 56 56   
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Pearson’s r=0.58, p<0.001, Pearson’s r=0.35, p<0.01, and Pearson’s r=0.59, p<0.001, 
respectively; Fig. 22a), between miR124 and miR1, miR129-2, and miR146a (Pearson’s 
r=0.58, p<0.001, Pearson’s r=0.74, p<0.001, and Pearson’s r=0.40, p<0.005, 
respectively), and between miR146a and miR1, miR21, and miR124 (Pearson’s r=0.59, 
p<0.001, Pearson’s r=0.69, p<0.001, and Pearson’s r=0.40, p<0.005, respectively; Fig. 
22b).    
 
4.4.2 Intermittent shock sensitivity of miRNA target genes 
4.4.2.1 Uncontrollable nociception had no significant effect on BDNF and IGF-1, 
mRNA targets of miR1, 1 hr following treatment 
As miR1 is further dysregulated by uncontrollable intermittent tailshock following 
contusion, we assessed the extent to which changes in miR1 expression corresponded to 
modulation of its neurotrophin and growth factor mRNA targets.  Accordingly, miR1 
has been shown to regulate the expression of both BDNF and IGF-1 (Lewis et al., 2003; 
Yu et al., 2008; Lee et al., 2012; Li et al., 2012).  To determine whether uncontrollable 
intermittent tailshock dysregulates BDNF and IGF-1 mRNAs, their expression was 
determined by qRT-PCR in sham controls and in response to either no shock exposure or 
uncontrollable intermittent tailshock following contusion.  As with the miRNA 
expression analysis, we first analyzed miRNA expression in full sections at 1 hr 
following treatment, and planned comparisons indicated that there was a significant 
decrease in expression of IGF-1 following contusion, irrespective of uncontrollable 
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intermittent tailshock (Student’s two-tailed t-test, pUnshock<0.01 and pShock<0.005; Figure 
23a, b).  
 
4.4.2.2 Multivariate ANOVA and post hoc univariate ANOVAs indicated a 
significant interaction effect of time and treatment on BDNF and IGF-1 expression 
Subsequently, spatial expression (dorsal/sensory-ventral/motor) of BDNF and IGF-1 
mRNA was assessed at 24 hrs and 7 days following SCIunshock or SCIshock treatment.  
Multivariate ANOVA of qRT-PCR data indicated a significant main effect of time 
(Pillai’s Trace Statistic, F(2,51)=5.198; p<0.01), treatment (F(4,104)=11.662; p<0.001), and 
spinal section (F(2,51)=17.966; p<0.001), and a significant interaction effect between both 
time and treatment (F(4,104)=6.29; p<0.001), and treatment and spinal section 
(F(4,104)=2.556; p<0.05).  Post hoc univariate ANOVAs indicated a main effect of time 
on IGF-1 mRNA (F(1,52)=9.491; p<0.005), a main effect of treatment on both BDNF and 
IGF-1 mRNAs (F(2,52)=10.672; p<0.001 and F(2,52)=30.133; p<0.001, respectively), and a 
main effect of spinal section on BDNF mRNA (F(1,52)=36.314; p<0.001). There was also 
a significant interaction effect of time and treatment on both BDNF and IGF-1 mRNA 
expression (F(2,52)=8.014; p<0.001 and F(2,52)=7.948; p<0.001, respectively), while 
BDNF mRNA expression was also significantly altered as a function of the interaction 
between time and spinal section (F(1,52)=5.437; p<0.05), treatment and spinal section 
(F(2,52)=5.323; p<0.01), and of time, treatment, and spinal section (F(2,52)=4.028; p<0.05).   
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Figure 23. Bar graphs depicting qRT-PCR analysis of mRNA expression of BDNF and IGF-1 at the 
lesion site for sham animals and after unshocked or shock treatment in contused animals at 1 hr following 
tailshock treatment.  (a) The x-axis denotes miRNA of interest, and the y-axis denotes the mean change in 
cycle threshold, where ΔCT represents the mean difference of mRNA and GAPDH control ΔCT values.  
Animals received either a laminectomy only (sham) or a T12-T13 spinal contusion followed by 
administration of unshock or shock 24 hrs later, and sacrificed at 1 hr following unshock/shock treatment 
for harvesting of the cords. Data are expressed relative to GAPDH controls (a value of zero equates to no 
difference in expression between the mRNA and GAPDH, positive values equate to higher miRNA 
expression, and negative values vice versa), with asterisks indicating significance (f-LSD) compared with 
sham controls; p values are as indicated in the text.  (b) The x-axis denotes mRNA of interest, and the y-
axis denotes the baseline-corrected percentage of fold expression change of mRNA using the formula (2-
ΔΔCT-1)*100, where ΔΔCT represents the mean difference of contused unshocked and sham, contused 
shocked and sham, or contused shocked and contused unshocked ΔCT values.  Data are expressed as a 
percentage of change (a value of zero equates to no change between surgery conditions), with asterisks 
indicating significance (f-LSD) compared with sham controls and hash tags indicating significance (f-
LSD) compared with contused unshocked controls; p values are as indicated in the text. 
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4.4.2.3 Uncontrollable nociception exhibited specific spatial and temporal 
dysregulation of BDNF and IGF-1 mRNA expression  
In addition, post hoc least significant difference (LSD) t-tests indicated that IGF-1 
expression was significantly decreased from 24 hrs to 7 days following SCIunshock or 
SCIshock treatment (pIGF-1<0.005).  BDNF mRNA was significantly decreased, while 
IGF-1 mRNA was significantly increased following spinal cord trauma, irrespective of 
uncontrollable intermittent tailshock or no shock exposure (pBDNF<0.001 and pIGF-
1<0.001, respectively; Figure 24a, b).  Furthermore, post hoc planned comparisons 
indicated that there was a significant decrease in expression of BDNF in dorsal/sensory 
tissue of SCIshock subjects relative to SCIunshock at 24 hrs following SCIunshock or SCIshock 
treatment (Student’s two-tailed t-test, p<0.001), but a significant increase in expression 
of IGF-1 mRNA in ventral/motor tissue at 7 days following SCIunshock or SCIshock 
treatment (p<0.05; Figure 24c, b).  Post hoc planned comparisons also indicated 
significant spatial changes (dorsal/sensory relative to ventral/motor) in mRNA 
expression, including increased relative dorsal/sensory expression of BDNF in sham, 
SCIunshock, and SCIshock treated subjects at both 24 hrs (p<0.01, p<0.001, and p<0.05, 
respectively) and 7 days following SCIunshock or SCIshock treatment (p<0.01, p<0.01, and 
p<0.001, respectively), and increased expression of IGF-1 in SCIshock subjects at 7 days 
following SCIunshock or SCIshock treatment (p<0.005; Figure 25a, b). 
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Figure 24. Bar graphs depicting qRT-PCR analysis of mRNA expression of BDNF and IGF-1 in dorsal 
and ventral sections at the lesion site for sham animals and after unshocked or shock treatment in contused 
animals at either 24 hrs (a, c) or 7 days (b, d) following tailshock treatment.  (a, c) The x-axis denotes 
mRNA of interest, and the y-axis denotes the mean change in cycle threshold, where ΔCT represents the 
mean difference of mRNA and GAPDH control ΔCT values.  Animals received either a laminectomy only 
(sham) or a T12-T13 spinal contusion followed by administration of unshock or shock 24 hrs later, and 
sacrificed at either 24 hrs or 7 days following unshock/shock treatment for harvesting and spatial 
sectioning of the cords. Data are expressed relative to GAPDH controls (a value of zero equates to no 
difference in expression between the mRNA and GAPDH, positive values equate to higher mRNA 
expression, and negative values vice versa), with asterisks indicating significance (f-LSD) compared with 
sham controls; p values are as indicated in the text.  (b, d) The x-axis denotes mRNA of interest, and the y-
axis denotes the baseline-corrected percentage of fold expression change of mRNA using the formula (2-
ΔΔCT-1)*100, where ΔΔCT represents the mean difference of contused unshocked and sham, contused 
shocked and sham, or contused shocked and contused unshocked ΔCT values.  Data are expressed as a 
percentage of change (a value of zero equates to no change between surgery conditions), with asterisks 
indicating significance (f-LSD) compared with sham controls and hash tags indicating significance (f-
LSD) compared with contused unshocked controls; p values are as indicated in the text. 
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Figure 25. Bar graphs depicting qRT-PCR analysis of percent fold change in mRNA expression of BDNF 
and IGF-1 in dorsal sections relative to ventral at the lesion site for sham animals and after unshocked or 
shock treatment in contused animals at either 24 hrs (a) or 7 days (b) following tailshock treatment.  (a, b) 
The x-axis denotes mRNA of interest, and the y-axis denotes the baseline-corrected percentage of fold 
expression change of mRNA using the formula (2-ΔΔCT-1)*100, where ΔΔCT represents the mean 
difference of dorsal and ventral ΔCT values for each treatment (ΔCT represents the mean difference of 
mRNA and GAPDH control ΔCT values).  Data are expressed as a percentage of change (a value of zero 
equates to no change between spinal sections), with asterisks indicating significance (f-LSD) compared 
with ventral expression; p values are as indicated in the text. 
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4.4.2.4 Correlation analyses indicated that expression changes of multiple SCI-
sensitive miRNAs were associated with changes in BDNF and IGF-1 expression 
As BDNF and IGF-1 are mRNA targets of miR1, we hypothesized that a statistical 
relationship would exist between expression changes in miR1 and that of BDNF and 
IGF-1.  Pearson’s product-moment correlations indicated two groups of significant 
correlations between SCI-sensitive miRNAs, BDNF, and IGF-1.  There were significant 
correlations between BDNF and both miR21 and miR124 (Pearson’s r=0.33, p<0.01 and 
Pearson’s r=-0.29, p<0.05, respectively), and between IGF-1 and miR1, miR124, 
miR129-2, and miR146a (Pearson’s r=0.40, p<0.005, Pearson’s r=0.47, p<0.001, and 
Pearson’s r=0.42, p<0.001, respectively).  BDNF and IGF-1 also significantly, but 
inversely correlated with each other (Pearson’s r=-0.31, p<0.05).  Further analysis using 
stepwise linear regression indicated that the variance in miR21 and miR146a 
significantly explained the variance in BDNF (F(1,46)=4.096; p<0.05), and that the 
variance in miR124, miR21, and miR146a significantly explained the variance in IGF-1 
(F(1,46)=8.149; p<0.01).  Interestingly, while miR1 exhibits a significant correlation with 
IGF-1, the stepwise linear regression model indicated that miR124, miR129-2, and 
miR146a significantly explains the majority of the variance in IGF-1 independent of 
miR1. 
 
4.5 Discussion 
One of the current clinical challenges with mitigating the short and long-term effects of 
spinal cord injury is managing the uncontrollable nociception that results from 
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concomitant peripheral tissue damage.  It is critical for future efforts to develop 
therapeutic strategies to attenuate glial activation, cell death, and sensitization of spinal 
neurons associated with intermittent noxious stimulation in order to inhibit maladaptive 
spinal plasticity, improve functional recovery, and suppress pain hypersensitivity 
following SCI with peripheral injuries (Liu et al., 1999; Frei et al., 2000; Beattie et al., 
2002; Hains et al., 2003; Xu et al., 2004; Hains and Waxman, 2006; Lampert et al., 
2006; Detloff et al., 2008; Kuzhandaivel et al., 2011).  As uncontrollable nociception 
inhibits functional recovery, nociceptive stimuli may directly alter biology within 
damaged tissue at the injury site.  Given their dysregulation following SCI and ability to 
coordinate the expression of large gene networks, it is possible that miRNAs are 
involved in the modulation of nociceptive circuitry and prevention of functional 
recovery resulting from uncontrollable nociception.  Therapeutic manipulation of these 
miRNAs could alleviate the maladaptive effects of noxious stimulation on both the acute 
and chronic phases of SCI by suppressing activation of glia-mediated inflammation and 
inhibiting the synaptic remodeling of nociceptive circuitry that results in pain 
hypersensitivity, increased spasticity, and exacerbation of behavioral deficits.   
 In the current study, we investigated the regulation of SCI-sensitive miRNAs at 
the lesion site immediately following uncontrollable intermittent tailshock, and in dorsal 
and ventral segments at 24 hrs and 7 days after SCIunshock and SCIshock treatment.   We 
found that uncontrollable intermittent tailshock significantly decreased expression of 
miR124 in dorsal/sensory tissue at 24 hrs post-SCI and significantly induced expression 
of miR129-2 in dorsal/sensory tissue and miR1 in ventral/motor tissue at 7 days 
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following SCIunshock and SCIshock treatment.  This is the first evidence for the potential 
involvement of miRNAs and, consequently, miRNA-regulated gene networks, as 
mediators of uncontrollable nociception’s effects on plasticity in the spinal cord, and 
indicates that peripheral noxious stimulation modulates gene networks and signaling 
pathways within the lesion site itself.  Expression changes in miR1 and miR124, in 
response to uncontrollable intermittent tailshock, also corresponded to a shift in spatial 
expression from predominately sensory neural tissue to motor or vise versa, along with 
miR146a, which was not significantly changed by uncontrollable intermittent tailshock.  
In addition, changes in expression of miR124 were significantly explained by the 
variance in expression of miR1, miR129-2, and miR146a, suggesting that these miRNAs 
may be co-regulated.  Collectively, these data suggest that uncontrollable nociception 
may modulate SCI-sensitive miRNA networks to affect spatially specific alterations to 
sensorimotor neuro-circuitry and signaling pathways involved in activation of microglia 
and inflammation at the lesion site.  Firstly, miR124 drives neuronal differentiation 
through a negative feedback loop that inhibits REST-mediated repression of neuronal 
genes while simultaneously down-regulating non-neuronal genes (Visvanathan et al., 
2007).  Furthermore, miR124 has been recently shown to promote microglia and 
macrophage quiescence and inhibit inflammatory nociception (Ponomarev et al., 2011; 
Willemen et al., 2012; Kynast et al., 2013).  Peripheral noxious stimulation led to 
significant down-regulation of miR124, with further inhibition exacerbating nociceptive 
behavior and administration of exogenous miR124 mimics attenuating nociception 
(Kynast et al., 2013).  Secondly, MiR1 has been shown to regulate IGF-1, which is 
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produced by activated microglia in the central nervous system, and inhibition of miR1 is 
neuroprotective in stroke models (Kerr and Patterson, 2005; Lalancette-Hebert et al., 
2007; Yu et al., 2008; Li et al., 2012; Selvamani et al., 2012).  Thirdly, the miR129 
family maintains cell cycle arrest in post-mitotic neurons through inhibition of G1/S 
phase-specific regulator cyclin-dependent kinase 6 (CDK6), and aberrant cell cycle entry 
resulting from suppression of miR129 can result in significant neuronal death (Di 
Giovanni et al., 2003; Byrnes et al., 2007; Herrup and Yang, 2007; Wu et al., 2010).  
Finally, miR146a not only plays an important role in innate immune response (Taganov 
et al., 2006; Nahid et al., 2009; Li et al., 2010a; Li et al., 2010b), but it has also been 
shown to be a negative feedback regulator of reactive astrocyte-mediated inflammatory 
response (Iyer et al., 2012).    
   Interestingly, we observed that although there was initially significant down-
regulation of IGF-1 at 1 hr following uncontrollable intermittent tailshock, it was 
significantly induced in response to contusion at both 24 hrs and 7 days in both 
dorsal/sensory and ventral/motor tissue, and uncontrollable intermittent tailshock 
induced additional significant up-regulation at 7 days after SCIunshock and SCIshock 
treatment in dorsal tissue.  Consistent with our previous findings (Garraway et al., 2011), 
we found that BDNF expression was significantly down-regulated at 24 hrs following 
uncontrollable intermittent tailshock in both the dorsal and ventral tissue, and additional 
significant BDNF suppression by uncontrollable intermittent tailshock was confined to 
the dorsal/sensory section of the spinal cord.  We also observed that changes in 
expression of IGF-1 were significantly explained in a linear regression model by the 
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variance in miR124, miR21, and miR146a, and that changes in BDNF expression were 
significantly explained by the variance in miR21 and miR124 expression, suggesting 
that both BDNF and IGF-1 regulation involves a network of miRNAs.  Surprisingly, 
changes in neither BDNF nor IGF-1 expression was significantly explained by the 
variance in miR1, despite its sensitivity to uncontrollable intermittent tailshock and 
microglia-specific involvement in regulating IGF-1 after stroke (Selvamani et al., 2012), 
and both miR1 and IGF-1 were both significantly up-regulated by uncontrollable 
nociception, suggesting a dissociation between miRNA and target gene networks 
following SCI and intermittent noxious stimulation, as have been observed in other 
models of neural damage (Pappalardo et al., 2013).  Regardless, as miR124 suppresses 
activation of resting microglia and macrophages prior to injury, and both miR21 and 
miR146a have been shown to negatively regulate astrocyte activation following SCI 
(Ponomarev et al., 2011; Bhalala et al., 2012; Iyer et al., 2012; Willemen et al., 2012; 
Kynast et al., 2013), these miRNAs may constitute therapeutic targets for attenuating the 
maladaptive effects of uncontrollable nociception at the lesion site through inhibition of 
glial activation.  In particular, miR124 is an especially attractive candidate, as it is 
involved in the regulation of both BDNF and IGF-1, sensitive to uncontrollable 
intermittent tailshock, and has been shown to inhibit nociceptive behavior associated 
with neuropathic pain (Kynast et al., 2013).  However, because IGF-1 both promotes 
oligodendrocyte survival after SCI upon up-regulation through leukemia inhibitory 
factor-mediated activation of microglia (Kerr and Patterson, 2005; Mekhail et al., 2012), 
and reduces blood-brain barrier permeability and edema through attenuation of nitric 
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oxide synthase up-regulation upon its topical application prior to and following SCI 
(Sharma et al., 1997; Nyberg and Sharma, 2002), exogenous IGF-1 and other growth 
factors may need to be given in conjunction with miRNA treatments to prevent further 
destabilization of the blood-brain barrier.   
 
4.6 Conclusion 
Our evidence shows that uncontrollable intermittent noxious stimulation results in a very 
specific and limited profile of changes in SCI-sensitive miRNA expression within the 
lesion site in both the acute and chronic phase of injury.  Because expression changes are 
confined to miRNAs, miR1, miR124, and miR129-2, that are involved in the regulation 
of microglia activation and cell cycle, and miR124 has been shown in other studies to 
attenuate the microglia activation-driven nociceptive behavior of neuro-inflammatory 
models of neuropathic pain, trauma-sensitive miRNAs that are further dysregulated by 
uncontrollable stimulation may serve as therapeutic targets and contribute towards 
regulation of neuropathic pain through modulation of glial activity.  Consequently, it 
will be interesting to see if miR124, along with miR1 and miR129-2, exhibit similar 
anti-nociceptive effects in future studies of SCI-based neuropathic pain models.   
Additionally, IGF-1 was persistently up-regulated following SCI, induced by 
uncontrollable intermittent tailshock in dorsal/sensory tissue at 7 days after SCIunshock 
and SCIshock treatment, and appeared to be either directly or indirectly co-regulated by 
miR124, miR21, and miR146a, all negative regulators of microglia and astrocyte 
activation, indicating that dysregulation of this miRNA network may play a role in the 
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development of neuropathic pain.  Furthermore, changes in neither IGF-1 nor BDNF 
expression exhibited a statistical relationship with changes in miR1 expression, and both 
IGF-1 and miR1 were up-regulated by uncontrollable nociception, suggesting a 
dissociation between miRNA and target gene networks following SCI and intermittent 
noxious stimulation.  Collectively, these data suggest that SCI-sensitive miRNAs 
constitute an important component in response to uncontrollable nociception from 
peripheral injury, possibly through regulation of microglia and astrocyte activation, and 
consequently, these miRNAs may constitute therapeutic targets for attenuating 
neuropathic pain following SCI. 
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5. CONCLUSION 
 
5.1 Overview 
The experiments in this dissertation were designed to determine the extent of miRNA 
dysregulation following spinal cord contusion and its implications in neuroinflammation, 
secondary injury, and neuropathic pain.  Our evidence shows that SCI results in a very 
specific and limited profile of miRNA expression changes that unfold in a coordinated 
manner following injury, and that these SCI-sensitive miRNAs play an important role in 
mediating the maladaptive effects of uncontrollable nociception and morphine-induced 
escalation of pain-sensitivity (Table 3).  Changes in miRNA-driven regulation of protein 
coding gene networks are mostly confined to the lesion site, with minimal adaptations 
within the surrounding tissue, and both miR129-2 and mir146a exhibit strong potential 
to be proxy markers for injury severity.  MiRNA and cellular marker expression patterns 
indicated that miRNA dysregulation might play a role in stem cell niche activation and 
in loss of neuronal identity that might drive neuronal apoptosis and progression of 
secondary injury.  In addition, miRNA dysregulation also plays a role in pain-sensitivity 
as morphine administration induced up-regulation of miR21 and IL6R expression, which 
is likely mediated through increased microglia activation, and modulation of miR21 may 
act as a counter-balance to keep neuroinflammation in check.  Uncontrollable 
nociception modulated expression of SCI-sensitive miRNAs that inhibit cell cycle 
proteins and microglial activation, along with BDNF and IGF-1, and dysregulation of  
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Table 3. Summary of miRNA expression changes following spinal cord contusion, morphine 
administration, and uncontrollable nociception.  For each miRNA and treatment group given by row and 
column heading, the direction change of regulation, denoted as either Down, Up, or non-significant (N/S), 
the baseline-corrected percentage of fold expression change of miRNA using the formula (2-ΔΔCT-1)*100, 
where ΔΔCT represents the mean difference of dorsal and ventral ΔCT values for each treatment (ΔCT 
represents the mean difference of miRNA and U6 control ΔCT values), and the p value based on Student’s 
two-tailed t-test, are listed in order from top to bottom, respectively.  Bolded treatment groups denote a 
significance of p<0.05. 
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these miRNAs likely contributes towards the hypersensitivity of spinal neurons that 
underlies neuropathic pain.   
  
5.2 Temporal Expression Patterns of SCI-Sensitive MiRNAs 25 Hours to 14 Days 
Following Contusion 
Analyses of changes in miRNA expression over the entire time course across all three 
experiments, in response to contusion only, illustrated several interesting trends in SCI-
driven modulation of miRNA expression profiles (Figure 26).  Quantitative RT-PCR 
data was compiled for “contusion” groups at each corresponding time point (i.e., 
contused groups from experiment 1 at 4 and 14 days post-SCI, and contused with no 
shock exposure treatment groups from experiment 3 at 25 hrs, 2 days, and 8 days post-
SCI), and changes in cycle threshold between miRNA and U6 ΔCT values were 
averaged for all subjects in each treatment group for both dorsal and ventral spinal 
sections, to approximate whole cord expression at 2 days and 8 days following contusion 
(24 hrs and 7 days following no shock exposure treatment, respectively).  Data from the 
contused with vehicle treatment groups in experiment 2 were omitted from the analysis 
due to redundant time points and inconsistent expression as compared to the other 
groups, most likely due to potential neuroinflammatory effects resulting from vehicle 
injection and distal nociception from tail-flick testing.  Of particular interest, miR21 
exhibited significant up-regulation as early as 25 hrs following injury, with significantly 
increased expression sustained through 8 days after SCI, and expression gradually 
decreased from peak expression at 25 hrs through 14 days post-SCI, at which point  
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Figure 26. Bar graphs depicting qRT-PCR analysis of percent fold change in temporal miRNA expression 
of miR1, miR21, miR124, miR129-2, and miR146a at the lesion site after contusion and relative to sham 
controls for 4 and 14 days post-SCI, and after contusion and no shock treatment relative to sham controls 
at either 25 hrs, 2 days, or 8 days following SCI (1 hr, 24 hrs, and 7 days post-tailshock treatment, 
respectively).  The x-axis denotes time following SCI, and the y-axis denotes the baseline-corrected 
percentage of fold expression change of miRNA using the formula (2-ΔΔCT-1)*100, where ΔΔCT 
represents the mean difference of dorsal and ventral ΔCT values for each treatment (ΔCT represents the 
mean difference of miRNA and U6 control ΔCT values).  Data are expressed as a percentage of change (a 
value of zero equates to no change between spinal sections), with asterisks indicating significance (f-LSD) 
compared with ventral expression; p values are as indicated in Section 2.4.1 and Section 4.4.1. 
  
 
120 
miR21 was significantly down-regulated relative to sham controls.  Conversely, miR124 
was significantly down-regulated starting at 2 days post-SCI, and expression levels 
persistently decreased through 14 days following contusion.  Given their respective roles 
in mediating quiescence of microglia and astrocytes (Ponomarev et al., 2011; Bhalala et 
al., 2012; Willemen et al., 2012), the temporal expression patterns of miR21 and miR124 
likely reflect neuroinflammation-driven increases in gliosis at the lesion site. 
  
5.3 Commonality of MiRNA Dysregulation in CNS Injury 
Importantly, SCI-sensitive miRNAs are also dysregulated following other types of CNS 
injury, suggesting that there may be specific networks of miRNAs that play major roles 
in the progression of CNS pathology and that multiple types of CNS injury may share 
common therapeutic targets.  Up-regulation of miR1 and miR124 has been observed 
within 24 hours of stroke, whereas miR21 and miR146a expression has been shown to 
be increased, as well as miR124 expression decreased, 7 days after stroke in neural 
progenitor cells within the subventricular zone (Jeyaseelan et al., 2008; Liu et al., 2010; 
Liu et al., 2011).  Similarly, expression of both miR21 and miR146a is significantly 
induced after traumatic brain injury, and miR21 closely mirrors the temporal expression 
pattern observed in SCI, with peak expression at 3 days after injury followed by a 
gradual reduction back to sham levels of expression by 15 days post-TBI  (Lei et al., 
2009; Saugstad, 2010; Redell et al., 2011; Thounaojam et al., 2013).  As most studies in 
stroke and TBI have focused on changes that occur with the first 24-72 hrs, it will be 
interesting to see if future research indicates additional consistencies in miRNA 
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dysregulation between stroke, TBI, and SCI during both the intermediate and later stages 
of injury.   
  
5.4 Potential of SCI-Sensitive MiRNAs to Regulate Extracellular mRNA 
Expression and Serve as Biomarkers of Injury Severity   
Spinal cord injury-sensitive miRNAs may also play a role in injury progression beyond 
the cellular compartment and exhibit regulatory effects outside of the lesion site, as 
miRNAs have been shown to be secreted by cells and both stable and detectable in 
serum, plasma, and cerebrospinal fluid (Cogswell et al., 2008; Gilad et al., 2008; 
Mitchell et al., 2008; Michael et al., 2010; Redell et al., 2010).  Secreted miRNAs from 
cells within the lesion site could exert mRNA regulation in nearby cells, thereby 
directing a coordinated shift in mRNA expression profiles within groups of damaged cell 
populations as an adaptive response to SCI.  In addition, SCI-sensitive miRNAs may 
serve as biomarkers for injury severity through their detection in blood serum, especially 
miR129-2 and miR146a, as we found that changes in their expression were predictive of 
functional deficits 24 hours following SCI.  Numerous miRNAs have been shown to be 
dysregulated in blood plasma following both stroke and TBI, including an over 5-fold 
decrease in miR146a expression within the first 24 hours of severe TBI in human 
patients (Jeyaseelan et al., 2008; Liu et al., 2010; Redell et al., 2010).  Additionally, a 
combined assessment of 3 TBI-sensitive miRNAs expressed only in the plasma of TBI 
patients exhibited substantial diagnostic accuracy (Redell et al., 2010), suggesting that 
SCI-sensitive miRNAs may also exhibit differential expression in blood plasma 
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following injury and serve as effective clinical biomarkers.   Expression levels of 
established miRNA biomarkers for injury severity could then be measured in patient 
blood serum to determine the corresponding expression of key mRNA targets or degree 
of neuroinflammation within the lesion site, which would allow for metering of potential 
miRNA therapeutics to carefully optimize dosage to enhance functional recovery. 
  
5.5 Potential Role of Distal Nociception after SCI in MiRNA-Target mRNA 
Network Dissociations and Extracellularly Initiated Regulation of MiRNAs  
We also found that expression changes in miR1, miR124, and miR129-2 significantly 
explained the variance in pain sensitivity following SCI, suggesting that these miRNAs 
play a role in the regulation of nociceptive signaling pathways and that distal nociception 
likely modulates their expression.  In addition, models of acute and neuropathic pain also 
result in dissociation between expression of both miR21 and miR1 and regulation of 
their mRNA targets.  Concurrent up-regulation of miR21 and IL6R following morphine 
administration and of miR1 and IGF-1 following uncontrollable nociception lends 
further evidence that distal nociceptive stimulation can regulate expression changes in 
SCI-sensitive miRNAs within the lesion site.  This regulation is likely a result of 
damaged neuronal circuitry at the lesion site being incapable of properly responding to 
distal nociceptive signaling in the form of neurotransmitter release, leading to 
accumulation of excitatory neurotransmitters and exacerbated activation of nearby 
microglia and astrocytes.  Increased extracellular signaling and binding of surface 
receptors can activate multiple signaling pathways capable of regulating specific miRNA 
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expression.  For example, ethanol has been shown to selectively suppress miR21 
expression in neural stem cells through activation of GABAA receptor-dependent 
mechanisms (Sathyan et al., 2007).  Activation of these receptor mediated intracellular 
signaling pathways can trigger phosphorylation cascades with the capacity to modulate 
multiple aspects of miRNA biogenesis.  Specifically, activation of the mitogen-activated 
protein kinase (MAPk) pathway has been shown to lead to phosphorylation of a 
component of the Drosha/DGCR8 pri-miRNA processing complex, RNA helicase 
P68/DDX5 (Hong et al., 2013).  In addition, MAPk can modulate activity of the RISC 
complex through phosphorylation of the Argonaute 2 protein at a serine residue, thereby 
preventing its localization with processing bodies, or at a tyrosine residue within the 
RNA binding region that reduces binding of miRNAs and, consequently, their ability to 
inhibit translation (Zeng et al., 2008; Rudel et al., 2011).  Similar regulation of 
Argonaute protein phosphorylation may contribute to the dissociations in miRNA and 
mRNA target networks following SCI and distal nociception, as phosphorylation within 
specific sites of the RNA binding region may alter protein folding in a functionally 
selective manner.  The modulated RNA binding region could reduce binding of a 
majority of miRNAs, while allowing for a few specific miRNAs to maintain the same 
binding affinity with reduced interference from competing miRNAs.  Distal nociception-
induced dissociations could occur both from highly expressed miRNAs being unable to 
form stable complexes with RISC, allowing mRNA target translation to occur with 
reduced inhibition (i.e., up-regulation of both miRNA and mRNA target expression), and 
from lower expressed miRNAs being preferentially loaded onto RISC in the presence of 
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reduced binding competition, yielding increased inhibition of mRNA targets without the 
need for a corresponding increase in initial miRNA expression.  Furthermore, increased 
activation of phosphorylation signaling pathways can also lead to increased activation or 
inactivation of transcription factors that either directly or indirectly regulate 
transcriptional expression of miRNAs, which could synergistically enhance these 
miRNA-mRNA target dissociations following SCI and distal nociception.  
 
5.6 Future Directions 
While these SCI-sensitive miRNAs hold potential as therapeutic targets, additional 
studies are needed to determine their ability to improve functional recovery, mitigate 
neuropathic pain, and block the maladaptive effects of morphine administration. In vivo 
studies examining the effects of exogenous administration of individual SCI-sensitive 
miRNA mimics and anti-miRNAs following SCI could indicate the regulatory effects of 
specific miRNAs on functional behavior and, in conjunction with the use of gene and 
miRNA microarrays, immunofluorescence, and in situ hybridization, could elucidate 
their specific effects on SCI pathology-associated gene networks, inflammation, 
apoptosis, and glial activation in the damaged spinal cord.  The increased understanding 
of miRNA function on the SCI microenvironment would allow for more effective 
development of therapeutics by indicating which combinations of different miRNA 
mimics and anti-miRNAs could be the most effective at minimizing secondary injury, 
promoting regeneration within the lesion site, improving functional recovery, and 
attenuating neuropathic pain.  In addition, analysis of global gene expression changes 
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due to miRNA manipulations could also indicate important factors that are beneficial to 
injury mitigation, such as BDNF and IGF-1, but adversely impacted by miRNA 
treatments.  Correspondingly, exogenous administration of these compromised factors to 
the lesion site, in addition to selected miRNA mimics and anti-miRNAs, could optimize 
the effectiveness of miRNA therapeutics by mitigating potential maladaptive regulation.  
For example, miR124 is a promising candidate for preventing neuropathic pain, as it is 
sensitive to uncontrollable nociception, suppresses activation of resting microglia and 
macrophages prior to injury, and has been shown to inhibit nociceptive behavior 
associated with peripheral noxious stimulation (Ponomarev et al., 2011; Willemen et al., 
2012; Kynast et al., 2013).  However, because miR124 plays a role in IGF-1 regulation, 
which is beneficial following SCI through promotion of oligodendrocytes survival and 
restoration of the blood-spinal cord barrier (Sharma et al., 1997; Nyberg and Sharma, 
2002; Kerr and Patterson, 2005; Mekhail et al., 2012), IGF-1 may need to be included 
with miR124 administration to maximize effectiveness.  Consequently, thorough 
analyses of the regulatory and physiological effects of in vivo miRNA manipulation 
following contusion injury, uncontrollable nociception, and morphine administration 
could uncover novel therapeutic strategies to substantially improve functional outcomes 
and prevent neuropathic pain in human patients.  
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